Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Diabetes

  Free Subscription


Articles published in Diabetes Obes Metab

Retrieve available abstracts of 456 articles:
HTML format
Text format



Single Articles


    August 2018
  1. KAKU K, Haneda M, Tanaka Y, Lee G, et al
    Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2018 Aug 9. doi: 10.1111/dom.13496.
    PubMed     Text format     Abstract available


  2. CHEN HF, Ho CA, Li CY
    Risk of heart failure in type 2 diabetes population: Comparison with non-diabetes subjects with and without coronary heart diseases.
    Diabetes Obes Metab. 2018 Aug 8. doi: 10.1111/dom.13493.
    PubMed     Text format     Abstract available


  3. BAILEY CJ, Marx N
    Cardiovascular protection in type 2 diabetes: insights from recent outcome trials.
    Diabetes Obes Metab. 2018 Aug 8. doi: 10.1111/dom.13492.
    PubMed     Text format     Abstract available


  4. CHRISTENSEN P, Meinert Larsen T, Westerterp-Plantenga M, Macdonald I, et al
    Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW).
    Diabetes Obes Metab. 2018 Aug 7. doi: 10.1111/dom.13466.
    PubMed     Text format     Abstract available


  5. ELBAZ-GREENER G, Bloch O, Kumets I, Blatt A, et al
    Endogenous GLP-1 system response is impaired during St-elevation myocardial infarction in type 2 diabetes patients.
    Diabetes Obes Metab. 2018 Aug 6. doi: 10.1111/dom.13490.
    PubMed     Text format     Abstract available


  6. BAE JC, Min KW, Kim YH, Kim KA, et al
    Efficacy and safety of fixed-dose comBination therApy with gemigLiptin (50 mg) and rosuvAstatiN (20 mg) Compared with Each monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, p
    Diabetes Obes Metab. 2018 Aug 6. doi: 10.1111/dom.13491.
    PubMed     Text format     Abstract available


  7. MATIKAINEN N, Soderlund S, Bjornson E, Pietilainen K, et al
    Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomised controlled study.
    Diabetes Obes Metab. 2018 Aug 2. doi: 10.1111/dom.13487.
    PubMed     Text format     Abstract available


  8. NEYMAN A, Nelson J, Tersey S, Mirmira RG, et al
    Persistent Elevations in Circulating INS DNA Among Subjects with Longstanding Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Aug 2. doi: 10.1111/dom.13489.
    PubMed     Text format     Abstract available


  9. OUCHI M, Oba K, Suganami H, Yoshida A, et al
    This is in reply to the Letter by Kahathuduwa et al. titled "Unaccounted for regression to the mean renders conclusion of article titled 'Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin' unsubstantiated".
    Diabetes Obes Metab. 2018;20:2041-2042.
    PubMed     Text format    


    July 2018
  10. LIAN J, McGhee SM, So C, Chau J, et al
    Long-term cost-effectiveness of Patient Empowerment Programme for Type 2 Diabetes Mellitus in primary care.
    Diabetes Obes Metab. 2018 Jul 29. doi: 10.1111/dom.13485.
    PubMed     Text format     Abstract available


  11. AVGERINOS I, Karagiannis T, Malandris K, Liakos A, et al
    Glucagon-like peptide 1 receptor agonists and microvascular outcomes in type 2 diabetes: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Jul 29. doi: 10.1111/dom.13484.
    PubMed     Text format     Abstract available


  12. RENARD E, Tubiana-Rufi N, Bonnemaison-Gilbert E, Coutant R, et al
    Closed-Loop Driven by Control-to-Range Algorithm Outperforms Threshold-Low-Glucose-Suspend Insulin Delivery on Glucose Control Albeit not on Nocturnal Hypoglycemia in Pre-pubertal Patients with Type 1 Diabetes in Supervised Hotel Setting.
    Diabetes Obes Metab. 2018 Jul 25. doi: 10.1111/dom.13482.
    PubMed     Text format     Abstract available


  13. MOTTALIB A, Tomah S, Hafida S, Elseaidy T, et al
    Intensive Multidisciplinary Weight Management in Patients with Type 1 Diabetes and Obesity: a 1-Year Retrospective Matched Cohort Study.
    Diabetes Obes Metab. 2018 Jul 25. doi: 10.1111/dom.13478.
    PubMed     Text format     Abstract available


  14. SCHMEDT N, Andersohn F, Walker J, Garbe E, et al
    Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: a nested case-control study.
    Diabetes Obes Metab. 2018 Jul 25. doi: 10.1111/dom.13480.
    PubMed     Text format    


  15. TANG H, Yang K, Song Y, Han J, et al
    Meta-analysis of the association between sodium-glucose cotransporter 2 inhibitors and risk of skin cancer among patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Jul 23. doi: 10.1111/dom.13474.
    PubMed     Text format     Abstract available


  16. KU EJ, Lee DH, Jeon HJ, Oh TK, et al
    Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: an observational study in clinical practice.
    Diabetes Obes Metab. 2018 Jul 23. doi: 10.1111/dom.13476.
    PubMed     Text format     Abstract available


  17. DAWWAS GK, Smith SM, Park H
    Cardiovascular Outcomes of Sodium Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Jul 23. doi: 10.1111/dom.13477.
    PubMed     Text format     Abstract available


  18. SCOTT R, Morgan J, Zimmer Z, Lam RLH, et al
    A Randomized Clinical Trial of the Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Mild Renal Insufficiency: The CompoSIT-R Study.
    Diabetes Obes Metab. 2018 Jul 18. doi: 10.1111/dom.13473.
    PubMed     Text format     Abstract available


  19. BRUCE DG, Davis WA, Davis TM
    Glycaemic control and mortality in older people with type 2 diabetes: The Fremantle Diabetes Study Phase II.
    Diabetes Obes Metab. 2018 Jul 13. doi: 10.1111/dom.13469.
    PubMed     Text format     Abstract available


  20. JAVIER ESCALADA F, Halimi S, Senior PA, Bonnemaire M, et al
    Glycemic control and hypoglycemia benefits with insulin glargine 300 U/mL (Gla-300) extend to people with type 2 diabetes and mild-to-moderate renal impairment.
    Diabetes Obes Metab. 2018 Jul 13. doi: 10.1111/dom.13470.
    PubMed     Text format     Abstract available


  21. IDZERDA NMA, Persson F, Pena MJ, Brenner BM, et al
    NT-proBNP predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk.
    Diabetes Obes Metab. 2018 Jul 10. doi: 10.1111/dom.13465.
    PubMed     Text format     Abstract available


  22. KADOWAKI T, Sarai N, Hirakawa T, Taki K, et al
    Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics, and severity of renal impairment: A Japanese database analysis.
    Diabetes Obes Metab. 2018 Jul 4. doi: 10.1111/dom.13463.
    PubMed     Text format    


  23. ROSENSTOCK J, Handelsman Y, Vidal J, Ampudia Blasco FJ, et al
    Propensity score-matched comparative analyses of simultaneously administered fixed-ratio iGlarLixi (LixiLan) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
    Diabetes Obes Metab. 2018 Jul 4. doi: 10.1111/dom.13462.
    PubMed     Text format     Abstract available


  24. WANG JL, Dong YH, Ko WC, Chang CH, et al
    Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: a population-based cohort study.
    Diabetes Obes Metab. 2018 Jul 4. doi: 10.1111/dom.13461.
    PubMed     Text format     Abstract available


  25. HARJUTSALO V, Thomas MC, Forsblom C, Groop PH, et al
    Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes.
    Diabetes Obes Metab. 2018 Jul 2. doi: 10.1111/dom.13456.
    PubMed     Text format     Abstract available


  26. RIDDERSTRALE M, Rosenstock J, Andersen KR, Woerle HJ, et al
    Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
    Diabetes Obes Metab. 2018 Jul 2. doi: 10.1111/dom.13457.
    PubMed     Text format     Abstract available


  27. GUO L, Chen L, Chang B, Yang L, et al
    A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral
    Diabetes Obes Metab. 2018 Jul 2. doi: 10.1111/dom.13454.
    PubMed     Text format     Abstract available


    June 2018
  28. ZULLO AR, Hersey M, Lee Y, Sharmin S, et al
    Outcomes of "Diabetes-Friendly" versus "Diabetes-Unfriendly" Beta-blockers in Older Nursing Home Residents with Diabetes after Acute Myocardial Infarction.
    Diabetes Obes Metab. 2018 Jun 28. doi: 10.1111/dom.13451.
    PubMed     Text format     Abstract available


  29. MULLER-WIELAND D, Kellerer M, Cypryk K, Skripova D, et al
    Efficacy and Safety of Dapagliflozin or Dapagliflozin Plus Saxagliptin Versus Glimepiride as Add-on to Metformin in Patients With Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Jun 27. doi: 10.1111/dom.13437.
    PubMed     Text format     Abstract available


  30. FRIER BM, Landgraf W, Zhang M, Bolli GB, et al
    Hypoglycaemia risk in the first eight weeks of titration with insulin glargine 100 U/mL in previously insulin-naive people with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13450.
    PubMed     Text format     Abstract available


  31. SPILLER S, Bluher M, Hoffmann R
    Plasma levels of free fatty acids correlate with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13449.
    PubMed     Text format     Abstract available


  32. SULLIVAN SD, Bailey TS, Roussel R, Zhou FL, et al
    Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13345.
    PubMed     Text format     Abstract available


  33. RYAN PB, Buse JB, Schuemie MJ, DeFalco F, et al
    Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (O
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13424.
    PubMed     Text format     Abstract available


  34. WEIR DL, Abrahamowicz M, Beauchamp ME, Eurich DT, et al
    Acute vs Cumulative Benefits of Metformin use in Patients with Type 2 Diabetes and Heart Failure.
    Diabetes Obes Metab. 2018 Jun 23. doi: 10.1111/dom.13448.
    PubMed     Text format     Abstract available


  35. STEPHENSON JJ, Raval AD, Kern DM, Bae JP, et al
    Nonadherence to Basal Insulin Among Patients With Type 2 Diabetes in a US Managed Care Population: Results from a Patient Survey.
    Diabetes Obes Metab. 2018 Jun 21. doi: 10.1111/dom.13446.
    PubMed     Text format     Abstract available


  36. SUGIMOTO DH, Dex T, Stager W, Aroda VR, et al
    Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as high and low risk according to HEDIS measures.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13438.
    PubMed     Text format     Abstract available


  37. ALFREDSSON J, Green JB, Stevens SR, Reed SD, et al
    Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13377.
    PubMed     Text format     Abstract available


  38. MELMER A, Kempf P, Lunger L, Pieber TR, et al
    Short-term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion, and ketogenesis in type 1 diabetes - a randomized, placebo-controlled, double blind, cross-over pilot study.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13439.
    PubMed     Text format     Abstract available


  39. JAIKUMKAO K, Pongchaidecha A, Chueakula N, Thongnak LO, et al
    Dapagliflozin, a SGLT2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, ER stress, and apoptosis in pre-diabetic rats.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13441.
    PubMed     Text format     Abstract available


  40. ANDERSEN G, Meiffren G, Lamers D, DeVries JH, et al
    Ultra-rapid BioChaperone Lispro Improves post-prandial Blood Glucose Excursions versus Insulin Lispro in a 14-day crossover Treatment Study in Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13442.
    PubMed     Text format     Abstract available


  41. KAZIERAD DJ, Chidsey K, Somayaji VR, Bergman AJ, et al
    Efficacy and Safety of the Glucagon Receptor Antagonist PF-06291874: A 12-Week, Randomized, Dose-Response Study in Patients With Type 2 Diabetes Mellitus on Background Metformin Therapy.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13440.
    PubMed     Text format     Abstract available


  42. YAN Z, Shyr ZA, Fortunato M, Welscher A, et al
    High Fat Diet induced Remission of Diabetes in a subset of KATP -GOF Insulin Secretory-Deficient mice.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13423.
    PubMed     Text format     Abstract available


  43. KORSATKO S, Jensen L, Brunner M, Sach-Friedl S, et al
    Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in subjects with type 2 diabetes: a randomised, placebo-controlled, double-blind, crossover trial.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13422.
    PubMed     Text format     Abstract available


  44. RABBONE I, Minuto N, Toni S, Lombardo F, et al
    Insulin pump breakdown and infusion set failure in Italian children with type 1 diabetes: 1-year prospective observational study with suggestions to minimize clinical impact.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13419.
    PubMed     Text format     Abstract available


  45. TSURUTANI Y, Nakai K, Inoue K, Kosuke A, et al
    Comparative study of ipragliflozin with sitagliptin on multiple metabolic changes in Japanese patients with type 2 diabetes: a multicenter, randomized, prospective, open-label, active-controlled study.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13421.
    PubMed     Text format     Abstract available


  46. FIORETTO P, Del Prato S, Buse JB, Goldenberg R, et al
    Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes and Moderate Renal Impairment (Chronic Kidney Disease Stage 3A): The DERIVE Study.
    Diabetes Obes Metab. 2018 Jun 11. doi: 10.1111/dom.13413.
    PubMed     Text format     Abstract available


  47. TERAUCHI Y, Riddle MC, Hirose T, Koyama M, et al
    Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: a 12-month comparison by concomitant sulphonylurea and/or glinide use.
    Diabetes Obes Metab. 2018 Jun 11. doi: 10.1111/dom.13414.
    PubMed     Text format     Abstract available


  48. EMANUEL AL, de Clercq NC, Koopen AM, van Poelgeest E, et al
    Iloprost infusion prevents the insulin-induced reduction in skeletal muscle microvascular blood volume but does not enhance peripheral glucose uptake in type 2 diabetic patients.
    Diabetes Obes Metab. 2018 Jun 8. doi: 10.1111/dom.13410.
    PubMed     Text format     Abstract available


  49. NIMRI R, Dassau E, Segall T, Muller I, et al
    Adjusting insulin doses in patients with type 1 diabetes that use insulin pump and continuous glucose monitoring - Variations among countries and physicians.
    Diabetes Obes Metab. 2018 Jun 8. doi: 10.1111/dom.13408.
    PubMed     Text format     Abstract available


  50. FARR OM, Mantzoros CS
    Obese individuals with type 2 diabetes demonstrate decreased activation of the salience-related insula and increased activation of the emotion/salience-related amygdala to visual food cues compared to non-obese individuals with diabetes: a preliminary
    Diabetes Obes Metab. 2018 Jun 8. doi: 10.1111/dom.13403.
    PubMed     Text format     Abstract available


  51. REZNIK Y, Habteab A, Castaneda J, Shin J, et al
    Contribution of basal and postprandial hyperglycemia in type 2 diabetes patients treated by an intensified insulin regimen: impact of pump therapy in the OPT2MISE trial.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13398.
    PubMed     Text format     Abstract available


  52. HANS DEVRIES J, Desouza C, Bellary S, Unger J, et al
    Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13396.
    PubMed     Text format     Abstract available


  53. HAN KA, Chon S, Chung CH, Lim S, et al
    Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: a randomized controlled trial.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13394.
    PubMed     Text format     Abstract available


  54. KAKU K, Kuroda S, Ishida K, Umeda Y, et al
    Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: results from a randomized, phase IV study.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13397.
    PubMed     Text format     Abstract available


  55. JALVING AC, Gant CM, Binnenmars SH, Soedamah-Muthu SS, et al
    Glycemic Control In The Diabetes And Lifestyle Cohort Twente - A Cross-Sectional Assessment Of Lifestyle And Pharmacological Management On Hba1c Target Achievement.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13399.
    PubMed     Text format     Abstract available


  56. KREBS JD, Arahill J, Cresswell P, Weatherall M, et al
    The effect of additional mealtime insulin bolus using an insulin-to-protein ratio compared to to usual carbohydrate counting on postprandial glucose in those with Type 1 diabetes who usually follow a carbohydrate-restricted diet: a randomised cross-ov
    Diabetes Obes Metab. 2018 Jun 1. doi: 10.1111/dom.13392.
    PubMed     Text format     Abstract available


    May 2018
  57. GANDA OP, Plutzky J, Sanganalmath SK, Bujas-Bobanovic M, et al
    Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials.
    Diabetes Obes Metab. 2018 May 26. doi: 10.1111/dom.13384.
    PubMed     Text format     Abstract available


  58. NORONHA JC, Braunstein CR, Glenn A, Khan TA, et al
    Effect of Small Doses of Fructose and Allulose on Postprandial Glucose Metabolism in Type 2 Diabetes: A Double-blind, Randomized, Controlled, Acute Feeding Equivalence Trial.
    Diabetes Obes Metab. 2018 May 24. doi: 10.1111/dom.13374.
    PubMed     Text format     Abstract available


  59. DRUMMOND RS, Malkin S, Du Preez M, Lee XY, et al
    Management of type 2 diabetes with Fixed-Ratio combination insulin degludec/liraglutide (IDEGLIRA) versus Basal-Bolus therapy (INSULIN GLARGINE U100 PLUS INSULIN ASPART): A Short-Term Cost-Effectiveness analysis in the UK setting.
    Diabetes Obes Metab. 2018 May 24. doi: 10.1111/dom.13375.
    PubMed     Text format     Abstract available


  60. CAO B, Rosenblat JD, Brietzke E, Park C, et al
    Comparative Efficacy and Acceptability of Anti-Diabetic Agents for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Network Meta-analysis.
    Diabetes Obes Metab. 2018 May 23. doi: 10.1111/dom.13373.
    PubMed     Text format     Abstract available


  61. KAWASAKI R, Konta T, Nishida K
    Lipid-lowering medication use is associated with decreased risk of diabetic retinopathy and its treatments in patients with type 2 diabetes: a real-world observational analysis of a health claims database.
    Diabetes Obes Metab. 2018 May 22. doi: 10.1111/dom.13372.
    PubMed     Text format     Abstract available


  62. BELL DSH, Goncalves E
    Should we still be utilizing warfarin in the type 2 diabetic patient?
    Diabetes Obes Metab. 2018 May 22. doi: 10.1111/dom.13371.
    PubMed     Text format     Abstract available


  63. LESLIE RD, Pozzilli P, Peters AL, Buzzetti R, et al
    Response to the comment on Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2,-4 and -5 Trials.
    Diabetes Obes Metab. 2018 May 20. doi: 10.1111/dom.13366.
    PubMed     Text format     Abstract available


  64. SUZUKI R, Eiki JI, Moritoyo T, Furihata K, et al
    Effect of Short Term Treatment with Sitagliptin or Glibenclamide on Daily Glucose Fluctuation in Drug-naive Japanese Patients with Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 May 17. doi: 10.1111/dom.13364.
    PubMed     Text format     Abstract available


  65. KAWAMORI R, Haneda M, Suzaki K, Cheng G, et al
    Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13352.
    PubMed     Text format     Abstract available


  66. HOME PD, Lam RLH, Carofano WL, Golm GT, et al
    Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: a randomized, open-label clinical trial.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13354.
    PubMed     Text format     Abstract available


  67. AHREN B, Atkin SL, Charpentier G, Warren ML, et al
    Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in SUSTAIN 1-5 trials.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13353.
    PubMed     Text format     Abstract available


  68. SHIMADA A, Hanafusa T, Yasui A, Lee G, et al
    Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13351.
    PubMed     Text format     Abstract available


  69. HOLLANDER PA, Carofano WL, Lam RLH, Golm GT, et al
    Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: a randomized, open-label clinical trial.
    Diabetes Obes Metab. 2018 May 14. doi: 10.1111/dom.13363.
    PubMed     Text format     Abstract available


  70. ANDREADIS P, Karagiannis T, Malandris K, Avgerinos I, et al
    Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 May 13. doi: 10.1111/dom.13361.
    PubMed     Text format     Abstract available


  71. BAILEY CJ
    European Medicines Agency: approval of new glucose-lowering medicines for type 2 diabetes.
    Diabetes Obes Metab. 2018 May 13. doi: 10.1111/dom.13360.
    PubMed     Text format     Abstract available


  72. PETRI KCC, Ingwersen SH, Flint A, Zacho J, et al
    Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes.
    Diabetes Obes Metab. 2018 May 11. doi: 10.1111/dom.13358.
    PubMed     Text format     Abstract available


  73. CURTIN F, Bernard C, Levet S, Perron H, et al
    A new therapeutic approach for type 1 diabetes: rationale for GNbAC1 an anti-HERV-W-Env monoclonal antibody.
    Diabetes Obes Metab. 2018 May 10. doi: 10.1111/dom.13357.
    PubMed     Text format     Abstract available


  74. BLIND E, Janssen H, Dunder K, de Graeff PA, et al
    The European Medicines Agency's Approval of New Medicines for Type 2 Diabetes.
    Diabetes Obes Metab. 2018 May 8. doi: 10.1111/dom.13349.
    PubMed     Text format     Abstract available


  75. FITZPATRICK C, Chatterjee S, Seidu S, Bodicoat DH, et al
    Association of hypoglycaemia and cardiac arrhythmia risk in patients with diabetes mellitus: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 May 8. doi: 10.1111/dom.13348.
    PubMed     Text format     Abstract available


  76. CURTIS HJ, Dennis JM, Shields BM, Walker AJ, et al
    Time Trends and Geographical Variation in Prescribing of Drugs for Diabetes in England 1998-2017.
    Diabetes Obes Metab. 2018 May 7. doi: 10.1111/dom.13346.
    PubMed     Text format     Abstract available


  77. MAIORINO MI, Chiodini P, Bellastella G, Scappaticcio L, et al
    Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2018 May 7. doi: 10.1111/dom.13343.
    PubMed     Text format     Abstract available


  78. OVERBEEK J, Heintjes E, Huisman E, Tikkanen C, et al
    Clinical Effectiveness of Liraglutide versus Basal Insulin in a Real-world Setting: Evidence for Improved Glycaemic and Weight Control in Obese Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2018 May 3. doi: 10.1111/dom.13335.
    PubMed     Text format     Abstract available


  79. HUANG CJ, Wang WT, Sung SH, Chen CH, et al
    Blood Glucose Reduction by Diabetic Drugs with Minimal Hypoglycemia Risk for Cardiovascular Outcomes: Evidence from Meta-regression Analysis of Randomized Controlled Trials.
    Diabetes Obes Metab. 2018 May 2. doi: 10.1111/dom.13342.
    PubMed     Text format     Abstract available


    April 2018
  80. CHEN YH, Huang CN, Cho YM, Li P, et al
    Efficacy and safety of dulaglutide monotherapy compared to glimepiride in East Asian patients with type 2 diabetes in a multicenter, double-blind, randomized, parallel-arm, active comparator, phase 3 trial.
    Diabetes Obes Metab. 2018 Apr 30. doi: 10.1111/dom.13340.
    PubMed     Text format     Abstract available


  81. GOLDENBERG RM, Assimakopoulos P, Gilbert JD, Gottesman IS, et al
    A Practical Approach and Algorithm for Intensifying Beyond Basal Insulin in Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Apr 29. doi: 10.1111/dom.13337.
    PubMed     Text format     Abstract available


  82. ZHU XX, Zhu DL, Li XY, Li YL, et al
    Dorzagliatin (HMS5552), a Novel Dual Acting Glucokinase Activator, Improves Glycemic Control and Pancreatic beta-cell Function in Patients with Type 2 Diabetes: A 28-day Treatment Study Using Biomarker-Guided Patient Selection.
    Diabetes Obes Metab. 2018 Apr 29. doi: 10.1111/dom.13338.
    PubMed     Text format     Abstract available


  83. PANDEYA N, Huxley RR, Chung HF, Dobson AJ, et al
    Female reproductive history and risk of type 2 diabetes: a prospective analysis of 126,721 women.
    Diabetes Obes Metab. 2018 Apr 25. doi: 10.1111/dom.13336.
    PubMed     Text format     Abstract available


  84. WARREN M, Chaykin L, Trachtenbarg D, Nayak G, et al
    Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the SUSTAIN 1-5 trials.
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13331.
    PubMed     Text format     Abstract available


  85. LIU DM, Mosialou I, Liu JM
    Bone: another potential target to treat, prevent and predict diabetes.
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13330.
    PubMed     Text format     Abstract available


  86. COLLIER A, Connelly PJ, Hair M, Cameron L, et al
    Mortality risk is still higher in people with type 1 diabetes: a population-based cohort study (The Ayrshirre Diabetes fOllow-up Cohort (ADOC) study).
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13334.
    PubMed     Text format     Abstract available


  87. SIDORENKOV G, van Boven JFM, Hoekstra T, Nijpels G, et al
    HbA1c response after insulin initiation in patients with type 2 diabetes in real-life: identifying distinct subgroups.
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13332.
    PubMed     Text format     Abstract available


  88. OUT M, Top WMC, Lehert P, Schalkwijk CA, et al
    Long-term treatment with metformin in type 2 diabetes and vitamin D levels: A post hoc analysis of a randomised placebo-controlled trial.
    Diabetes Obes Metab. 2018 Apr 17. doi: 10.1111/dom.13327.
    PubMed     Text format    


  89. BLEVINS TC, Barve A, Sun B, Ankersen M, et al
    Efficacy and Safety of MYL-1501D Versus Insulin Glargine in Patients With Type 1 Diabetes After 52 Weeks: Results of the Phase 3 INSTRIDE 1 Study.
    Diabetes Obes Metab. 2018 Apr 15. doi: 10.1111/dom.13322.
    PubMed     Text format     Abstract available


  90. ANDERSEN ES, Lund A, Bagger JI, Andreasen C, et al
    Is glucagon-like peptide-1 fully protected by dipeptidyl peptidase 4 inhibitor administration in patients with type 2 diabetes?
    Diabetes Obes Metab. 2018 Apr 14. doi: 10.1111/dom.13321.
    PubMed     Text format     Abstract available


  91. PONTIROLI AE, Ceriani V
    Intranasal glucagon for hypoglycaemia in diabetic patients. An old dream is becoming reality?
    Diabetes Obes Metab. 2018 Apr 13. doi: 10.1111/dom.13317.
    PubMed     Text format     Abstract available


  92. BARNETT AH, Arnoldini S, Hunt B, Subramanian G, et al
    Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A Long-Term Cost-Effectiveness analysis.
    Diabetes Obes Metab. 2018 Apr 13. doi: 10.1111/dom.13318.
    PubMed     Text format     Abstract available


  93. FARNGREN J, Persson M, Ahren B
    Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes-a randomized, placebo-controlled study.
    Diabetes Obes Metab. 2018 Apr 12. doi: 10.1111/dom.13316.
    PubMed     Text format     Abstract available


    March 2018
  94. HEERSPINK HJL, Andress DL, Bakris G, Brennan JJ, et al
    Baseline characteristics and enrichment results of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial.
    Diabetes Obes Metab. 2018 Mar 31. doi: 10.1111/dom.13315.
    PubMed     Text format     Abstract available


  95. MATHIEU C, Del Prato S, Botros FT, Thieu VT, et al
    Effect of Once Weekly Dulaglutide by Baseline Beta-cell Function in People with Type 2 Diabetes in the AWARD Programme.
    Diabetes Obes Metab. 2018 Mar 30. doi: 10.1111/dom.13313.
    PubMed     Text format     Abstract available


  96. VOORMOLEN DN, DeVries JH, Sanson RME, Heringa MP, et al
    Continuous Glucose Monitoring during Diabetic Pregnancy (GlucoMOMS); a multicentre randomised controlled trial.
    Diabetes Obes Metab. 2018 Mar 30. doi: 10.1111/dom.13310.
    PubMed     Text format     Abstract available


  97. RADHOLM K, Chalmers J, Ohkuma T, Peters S, et al
    Use of the waist-to-height-ratio to predict cardiovascular risk in patients with diabetes: results from ADVANCE-ON.
    Diabetes Obes Metab. 2018 Mar 30. doi: 10.1111/dom.13311.
    PubMed     Text format     Abstract available


  98. BECKER RHA
    Comment to Heise, T, Norskov, M, Nosek, L, Kaplan, K, Famulla, S and Haahr, H. L. (2017), Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes. Diabetes Obes Met
    Diabetes Obes Metab. 2018 Mar 29. doi: 10.1111/dom.13308.
    PubMed     Text format     Abstract available


  99. HOU C, Xu Q, Diao S, Hewitt J, et al
    Mobile phone applications and self-management of diabetes: a systematic review with meta-analysis, meta-regression of 21 randomized trials, and GRADE.
    Diabetes Obes Metab. 2018 Mar 27. doi: 10.1111/dom.13307.
    PubMed     Text format     Abstract available


  100. ORSI E, Solini A, Bonora E, Fondelli C, et al
    Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Mar 26. doi: 10.1111/dom.13306.
    PubMed     Text format     Abstract available


  101. ARNOLD SV, Kosiborod M, Wang J, Fenici P, et al
    Burden of Cardio-Renal-Metabolic Conditions in Adults with Type 2 Diabetes within the Diabetes Collaborative Registry.
    Diabetes Obes Metab. 2018 Mar 25. doi: 10.1111/dom.13303.
    PubMed     Text format     Abstract available


  102. RUAN Y, Bally L, Thabit H, Leelarathna L, et al
    Hypoglycaemia Incidence and Recovery During Home Use of Hybrid Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Mar 25. doi: 10.1111/dom.13304.
    PubMed     Text format     Abstract available


  103. REED SD, Li Y, Leal J, Radican L, et al
    Longitudinal Medical Resources and Costs Among Type 2 Diabetes Patients Participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13292.
    PubMed     Text format     Abstract available


  104. FRIAS JP, Hardy E, Ahmed A, Ohman P, et al
    Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13296.
    PubMed     Text format     Abstract available


  105. GUO M, Ding J, Li J, Wang J, et al
    SGLT2 inhibitors and stroke risk in patients with type 2 diabetes: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13295.
    PubMed     Text format     Abstract available


  106. LI D, Shi W, Wang T, Tang H, et al
    SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13294.
    PubMed     Text format     Abstract available


  107. PICHE ME, Laberge AS, Brassard P, Arsenault BJ, et al
    Rosiglitazone lowers resting and blood pressure response to exercise in men with type 2 diabetes: a 1 year randomized study.
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13293.
    PubMed     Text format     Abstract available


  108. KIM YG, Jeon JY, Han SJ, Kim DJ, et al
    Sodium-glucose co-transporter 2 inhibitors and the risk for diabetic ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Diabetes Obes Metab. 2018 Mar 22. doi: 10.1111/dom.13297.
    PubMed     Text format     Abstract available


  109. MASTRACCI TL, Turatsinze JV, Book BK, Restrepo IA, et al
    Distinct Gene Expression Pathways in Islets from Individuals with Short- and Long-Duration Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Mar 22. doi: 10.1111/dom.13298.
    PubMed     Text format     Abstract available


  110. LAUBNER K, Riedel N, Fink K, Holl RW, et al
    Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus - a case control study.
    Diabetes Obes Metab. 2018 Mar 22. doi: 10.1111/dom.13300.
    PubMed     Text format     Abstract available


  111. YANG YS, Lim MH, Lee SO, Roh E, et al
    Fimasartan increases glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine.
    Diabetes Obes Metab. 2018 Mar 15. doi: 10.1111/dom.13282.
    PubMed     Text format     Abstract available


  112. JONES AG, McDonald TJ
    Comment on: Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.
    Diabetes Obes Metab. 2018 Mar 14. doi: 10.1111/dom.13290.
    PubMed     Text format     Abstract available


  113. MONTVIDA O, Shaw J, Blonde L, Paul SK, et al
    Long-term sustainability of glycaemic achievements with second-line anti-diabetic therapies in patients with type 2 diabetes: A real-world study.
    Diabetes Obes Metab. 2018 Mar 14. doi: 10.1111/dom.13288.
    PubMed     Text format     Abstract available


  114. POP LM, Mari A, Zhao TJ, Mitchell L, et al
    Roux-en-Y Gastric Bypass Compared to Equivalent Diet Restriction: Mechanistic Insights into Diabetes Remission.
    Diabetes Obes Metab. 2018 Mar 13. doi: 10.1111/dom.13287.
    PubMed     Text format     Abstract available


  115. BRIL F, Millan L, Kalavalpalli S, McPhaul MJ, et al
    Use of a Metabolomic Approach to Non-invasively Diagnose Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 Mar 12. doi: 10.1111/dom.13285.
    PubMed     Text format     Abstract available


  116. MOHANDAS C, Bonadonna R, Shojee-Moradie F, Jackson N, et al
    Ethnic differences in insulin secretory function between Black African and White European men with early type 2 diabetes.
    Diabetes Obes Metab. 2018 Mar 8. doi: 10.1111/dom.13283.
    PubMed     Text format     Abstract available


  117. JUNG HY, Kim B, Ji Y, Ryu HG, et al
    Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice.
    Diabetes Obes Metab. 2018 Mar 8. doi: 10.1111/dom.13284.
    PubMed     Text format     Abstract available


  118. SEAQUIST ER, Dulude H, Zhang XM, Rabasa-Lhoret R, et al
    A prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycemia in adults with type 1 diabetes in a real-world setting.
    Diabetes Obes Metab. 2018 Mar 5. doi: 10.1111/dom.13278.
    PubMed     Text format     Abstract available


  119. CEA-SORIANO L, Garcia-Rodriguez LA, Brodovicz KG, Masso Gonzalez E, et al
    Safety of Non-insulin glucose-lowering drugs in pregnant women with pre-gestational diabetes: a cohort study.
    Diabetes Obes Metab. 2018 Mar 2. doi: 10.1111/dom.13275.
    PubMed     Text format     Abstract available


  120. ALSALIM W, Persson M, Ahren B
    Different Glucagon Effects During DPP-4 Inhibition versus SGLT-2 Inhibition in Metformin-Treated Type 2 Diabetes Subjects.
    Diabetes Obes Metab. 2018 Mar 2. doi: 10.1111/dom.13276.
    PubMed     Text format     Abstract available


  121. BJORNSTAD P, Maahs DM, Roncal CA, Snell-Bergeon JK, et al
    Role of Bicarbonate Supplementation on Urine Uric Acid Crystals and Diabetic Tubulopathy in Adults with Type 1 Diabetes: A Brief Report.
    Diabetes Obes Metab. 2018 Mar 2. doi: 10.1111/dom.13274.
    PubMed     Text format     Abstract available


  122. HENRY RR, Muller-Wieland D, Taub PR, Bujas-Bobanovic M, et al
    Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome and without diabetes: Pooled data from 10 phase 3 trials.
    Diabetes Obes Metab. 2018 Mar 1. doi: 10.1111/dom.13273.
    PubMed     Text format     Abstract available


    February 2018
  123. HARASHIMA SI, Inagaki N, Kondo K, Maruyama N, et al
    Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: a 52-week, open-label, phase IV study.
    Diabetes Obes Metab. 2018 Feb 23. doi: 10.1111/dom.13267.
    PubMed     Text format     Abstract available


  124. GUJA C, Frias JP, Somogyi A, Jabbour S, et al
    Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study.
    Diabetes Obes Metab. 2018 Feb 23. doi: 10.1111/dom.13266.
    PubMed     Text format     Abstract available


  125. YAMADA T, Shojima N, Noma H, Yamauchi T, et al
    Sodium-glucose co-transporter 2 (SGLT2) inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2018 Feb 16. doi: 10.1111/dom.13260.
    PubMed     Text format     Abstract available


  126. HALUZIK M, Fulcher G, Pieber TR, Bardtrum L, et al
    Insulin degludec/insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia independent of baseline HbA1c levels, disease duration or BMI: A pooled meta-analysis of phase 3 studies in patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Feb 16. doi: 10.1111/dom.13261.
    PubMed     Text format     Abstract available


  127. JUNG CH, Rhee EJ, Lee WY, Min KW, et al
    A 52-week extension study of switching from gemigliptin vs. sitagliptin to gemigliptin only as an add-on to patients with type 2 diabetes inadequately controlled on metformin alone.
    Diabetes Obes Metab. 2018 Feb 13. doi: 10.1111/dom.13256.
    PubMed     Text format     Abstract available


  128. RAY KK, Leiter LA, Muller-Wieland D, Cariou B, et al
    Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.
    Diabetes Obes Metab. 2018 Feb 13. doi: 10.1111/dom.13257.
    PubMed     Text format     Abstract available


  129. PANTALONE KM, Patel H, Yu M, Lando LF, et al
    Dulaglutide 1.5 mg as an Add-on Option for Patients Uncontrolled on Insulin: Subgroup Analysis by Age, Duration of Diabetes and Baseline HbA1c.
    Diabetes Obes Metab. 2018 Feb 12. doi: 10.1111/dom.13252.
    PubMed     Text format     Abstract available


  130. WONG CKH, Jiao F, Tang EHM, Tong T, et al
    Direct medical costs of diabetes mellitus in the year of mortality and year before mortality.
    Diabetes Obes Metab. 2018 Feb 12. doi: 10.1111/dom.13253.
    PubMed     Text format     Abstract available


  131. LAFFIN LJ, Bakris GL
    Results of ACCORDIAN in Accord with Lower Blood Pressure Begetting Lower Mortality in Patients with Diabetes.
    Diabetes Obes Metab. 2018 Feb 9. doi: 10.1111/dom.13249.
    PubMed     Text format     Abstract available


  132. BUCKLEY LF, Dixon DL, Wohlford GF 4th, Wijesinghe DS, et al
    Effect of Intensive Blood Pressure Control in Patients with Type 2 Diabetes Mellitus Over 9 Years of Follow-Up: A Subgroup Analysis of High-Risk ACCORDION Trial Participants.
    Diabetes Obes Metab. 2018 Feb 9. doi: 10.1111/dom.13248.
    PubMed     Text format     Abstract available


  133. BALDASSARRE MPA, Andersen A, Consoli A, Knop FK, et al
    Cardiovascular biomarkers in clinical studies of type 2 diabetes.
    Diabetes Obes Metab. 2018 Feb 8. doi: 10.1111/dom.13247.
    PubMed     Text format     Abstract available


  134. GORMSEN LC, Sondergaard E, Christensen NL, Jakobsen S, et al
    Metformin does not Affect Postabsorptive Hepatic Free Fatty Acid Uptake, Oxidation or Resecretion in Humans: A 3-months Placebo Controlled Clinical Trial in Patients with Type 2 Diabetes and Healthy Controls.
    Diabetes Obes Metab. 2018 Feb 6. doi: 10.1111/dom.13244.
    PubMed     Text format     Abstract available


  135. HEERSPINK HJL, Andress DL, Bakris G, Brennan JJ, et al
    Rationale and protocol of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
    Diabetes Obes Metab. 2018 Feb 6. doi: 10.1111/dom.13245.
    PubMed     Text format     Abstract available


  136. KHUNTI K, Kosiborod M, Ray KK
    Legacy benefits of blood glucose, blood pressure and lipid control in people with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?
    Diabetes Obes Metab. 2018 Feb 6. doi: 10.1111/dom.13243.
    PubMed     Text format     Abstract available


  137. MALMSTROM H, Walldius G, Carlsson S, Grill V, et al
    Elevations of metabolic risk factors 20 years or more before diagnosis of type 2 diabetes - experience from the AMORIS study.
    Diabetes Obes Metab. 2018 Feb 5. doi: 10.1111/dom.13241.
    PubMed     Text format     Abstract available


  138. TRAN S, Retnakaran R, Zinman B, Kramer CK, et al
    Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.
    Diabetes Obes Metab. 2018;20 Suppl 1:68-76.
    PubMed     Text format     Abstract available


  139. DANDONA P, Ghanim H, Chaudhuri A
    Incretins: Beyond type 2 diabetes.
    Diabetes Obes Metab. 2018;20 Suppl 1:59-67.
    PubMed     Text format     Abstract available


    January 2018
  140. THUESEN ACB, Vaag A
    Perspectives on diabetes mortality due to residual confounding and reverse causality by common disease.
    Diabetes Obes Metab. 2018 Jan 30. doi: 10.1111/dom.13238.
    PubMed     Text format     Abstract available


  141. POZZILLI P, Leslie RD, Peters AL, Buzzetti R, et al
    Dulaglutide Treatment Results in Effective Glycemic Control in Latent Autoimmune Diabetes in Adults (LADA): A Post-Hoc Analysis of the AWARD-2, -4, and -5 Trials.
    Diabetes Obes Metab. 2018 Jan 27. doi: 10.1111/dom.13237.
    PubMed     Text format     Abstract available


  142. CAO YX, Liu HH, Dong QT, Li S, et al
    Effect of the PCSK9-monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Jan 27. doi: 10.1111/dom.13235.
    PubMed     Text format     Abstract available


  143. RETNAKARAN R, Choi H, Ye C, Kramer CK, et al
    A 2-year Trial of Intermittent Insulin Therapy versus Metformin for the Preservation of Beta-cell Function after Initial Short-term Intensive Insulin Induction in early Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Jan 27. doi: 10.1111/dom.13236.
    PubMed     Text format     Abstract available


  144. TANG H, Li G, Zhao Y, Wang F, et al
    Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: a network meta-analysis.
    Diabetes Obes Metab. 2018 Jan 25. doi: 10.1111/dom.13232.
    PubMed     Text format     Abstract available


  145. LIU H, Wang L, Zhang S, Leng J, et al
    One-year weight losses in the Tianjin Gestational Diabetes Mellitus Prevention Program: A Randomized Clinical Trial.
    Diabetes Obes Metab. 2018 Jan 23. doi: 10.1111/dom.13225.
    PubMed     Text format     Abstract available


  146. KREBS JD, Weatherall M, Corley B, Wiltshire E, et al
    Optimising the management of hypoglycaemia in people with Type 2 Diabetes. A randomised crossover comparison of a weight-based protocol compared with two fixed-dose glucose regimens.
    Diabetes Obes Metab. 2018 Jan 23. doi: 10.1111/dom.13231.
    PubMed     Text format     Abstract available


  147. KOFFERT J, Stahle M, Karlsson H, Iozzo P, et al
    Morbid obesity and type 2 diabetes alter intestinal fatty acid uptake and blood flow.
    Diabetes Obes Metab. 2018 Jan 20. doi: 10.1111/dom.13228.
    PubMed     Text format     Abstract available


  148. APPERLOO EM, Pena MJ, de Zeeuw D, Denig P, et al
    Individual variability in response to renin-angiotensin-aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: a primary care cohort study.
    Diabetes Obes Metab. 2018 Jan 18. doi: 10.1111/dom.13226.
    PubMed     Text format     Abstract available


  149. POLIDORI D, Iijima H, Goda M, Maruyama N, et al
    Intra- and Inter-Subject Variability for Increases in Serum Ketone Bodies in Patients With Type 2 Diabetes Treated With the Sodium Glucose Co-transporter 2 Inhibitor Canagliflozin.
    Diabetes Obes Metab. 2018 Jan 17. doi: 10.1111/dom.13224.
    PubMed     Text format     Abstract available


  150. DORENBOS E, Drummen M, Rijks J, Adam T, et al
    PREVIEW: Prevention of diabetes through lifestyle intervention in a multicentre study in Europe in children (10-17y). Design, methods, and baseline results.
    Diabetes Obes Metab. 2018 Jan 11. doi: 10.1111/dom.13216.
    PubMed     Text format     Abstract available


  151. ILANY J, Bhandari H, Nabriski D, Toledano Y, et al
    Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled on once daily basal insulin: a randomized, phase IV study.
    Diabetes Obes Metab. 2018 Jan 8. doi: 10.1111/dom.13214.
    PubMed     Text format     Abstract available


  152. PORKSEN NK, Linnebjerg H, Lam ECQ, Garhyan P, et al
    Basal Insulin Peglispro Increases Lipid Oxidation, Metabolic Flexibility, Thermogenesis And Ketone Bodies Compared To Insulin Glargine In Subjects With Type 1 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 Jan 8. doi: 10.1111/dom.13215.
    PubMed     Text format     Abstract available


  153. MATHIEU C, Bode BW, Franek E, Philis-Tsimikas A, et al
    Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): a 52-week, randomized, treat-to-target, phase 3 trial.
    Diabetes Obes Metab. 2018 Jan 8. doi: 10.1111/dom.13205.
    PubMed     Text format     Abstract available


  154. TERAUCHI Y, Tamura M, Senda M, Gunji R, et al
    Long-term safety and efficacy of tofogliflozin add-on to insulin in patients with type 2 diabetes: results from a 52-week, multicenter, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
    Diabetes Obes Metab. 2018 Jan 5. doi: 10.1111/dom.13213.
    PubMed     Text format     Abstract available


  155. JABBOUR SA, Frias JP, Guja C, Hardy E, et al
    Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin added to metformin monotherapy on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
    Diabetes Obes Metab. 2018 Jan 5. doi: 10.1111/dom.13206.
    PubMed     Text format     Abstract available


  156. MENEGHINI LF, Lee L, Gupta S, Preblick R, et al
    The association of hypoglycaemia severity and clinical, patient-reported and economic outcomes in US patients with type 2 diabetes using basal insulin.
    Diabetes Obes Metab. 2018 Jan 5. doi: 10.1111/dom.13208.
    PubMed     Text format     Abstract available


  157. PACKER M
    Have We Really Demonstrated the Cardiovascular Safety of Antihyperglycemic Drugs? Rethinking the Concepts of Macrovascular and Microvascular Disease in Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Jan 5. doi: 10.1111/dom.13207.
    PubMed     Text format     Abstract available


    December 2017
  158. PETTUS J, Reeds D, Santos Cavaiola T, Boeder S, et al
    Effect of a Glucagon Receptor Antibody (REMD-477) in Type 1 Diabetes: A Randomized Controlled Trial.
    Diabetes Obes Metab. 2017 Dec 28. doi: 10.1111/dom.13202.
    PubMed     Text format     Abstract available


  159. ZHOU FL, Xie L, Pan C, Wang Y, et al
    Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiated on basal insulin.
    Diabetes Obes Metab. 2017 Dec 26. doi: 10.1111/dom.13200.
    PubMed     Text format     Abstract available


  160. WINDING KM, Munch GW, Iepsen UW, Van Hall G, et al
    The effect of low-volume high-intensity interval training versus endurance training on glycemic control in individuals with type 2 diabetes.
    Diabetes Obes Metab. 2017 Dec 22. doi: 10.1111/dom.13198.
    PubMed     Text format     Abstract available


  161. ZHOU FL, Ye F, Berhanu P, Gupta VE, et al
    Real-world evidence on clinical and economic outcomes of switching to insulin glargine 300 Units/mL vs other basal insulins in patients with type 2 diabetes on basal insulin.
    Diabetes Obes Metab. 2017 Dec 22. doi: 10.1111/dom.13199.
    PubMed     Text format     Abstract available


  162. BUMBU A, Moutairou A, Matar O, Fumeron F, et al
    Non-severe hypoglycemia is associated with weight gain in patients with type 1 diabetes: Results from the Diabetes Control and Complication Trial.
    Diabetes Obes Metab. 2017 Dec 22. doi: 10.1111/dom.13197.
    PubMed     Text format     Abstract available


  163. CHON S, Rhee SY, Ahn KJ, Baik SH, et al
    Long-term outcome on glycaemic control and beta-cell preservation of early intensive treatment in patients with newly diagnosed Type 2 Diabetes: A Multicentre Randomised Trial.
    Diabetes Obes Metab. 2017 Dec 22. doi: 10.1111/dom.13196.
    PubMed     Text format     Abstract available


  164. PRATLEY RE, Eldor R, Raji A, Golm G, et al
    Ertugliflozin Plus Sitagliptin Versus Either Individual Agent Over 52 Weeks in Patients with Type 2 Diabetes Mellitus Inadequately Controlled With Metformin: The VERTIS FACTORIAL Randomized Trial.
    Diabetes Obes Metab. 2017 Dec 21. doi: 10.1111/dom.13194.
    PubMed     Text format     Abstract available


  165. WIGHTMAN SS, Sainsbury CAR, Jones GC
    Visit-to-visit HbA1c variability and systolic blood pressure (SBP) variability are significantly and additively associated with mortality in people with type 1 diabetes: an observational study.
    Diabetes Obes Metab. 2017 Dec 21. doi: 10.1111/dom.13193.
    PubMed     Text format     Abstract available


  166. PACKER M
    Role of the Sodium-Hydrogen Exchanger in Mediating the Renal Effects of Drugs Commonly Used in the Treatment of Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Dec 11. doi: 10.1111/dom.13191.
    PubMed     Text format     Abstract available


  167. ALSALIM W, Goransson O, Carr RD, Bizzotto R, et al
    Effect of a single dose of the DPP-4 inhibitor sitagliptin on beta-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naive, well-controlled type 2 diabetes subjects.
    Diabetes Obes Metab. 2017 Dec 11. doi: 10.1111/dom.13192.
    PubMed     Text format     Abstract available


  168. JI L, Liu J, Yang J, Li Y, et al
    Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naive Chinese patients: analysis of results from the CONSENT trial.
    Diabetes Obes Metab. 2017 Dec 11. doi: 10.1111/dom.13190.
    PubMed     Text format     Abstract available


  169. PRICE H, Bluher M, Prager R, Phan TM, et al
    Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study.
    Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13182.
    PubMed     Text format     Abstract available


  170. ZACCARDI F, Dhalwani NN, Dales J, Mani H, et al
    Comparison of glucose-lowering agents following dual therapy failure in type 2 diabetes Systematic review and network meta-analysis of randomised controlled trials.
    Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13185.
    PubMed     Text format     Abstract available


  171. EL KHOURY P, Roussel R, Fumeron F, Abou-Khalil Y, et al
    Plasma PCSK9 and Cardiovascular Events in Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13181.
    PubMed     Text format    


  172. HOME P, Calvi-Gries F, Blonde L, Pilorget V, et al
    Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study.
    Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13179.
    PubMed     Text format     Abstract available


    November 2017
  173. SISKIND D, Russell AW, Gamble C, Winckel K, et al
    Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: a randomised controlled trial.
    Diabetes Obes Metab. 2017 Nov 30. doi: 10.1111/dom.13167.
    PubMed     Text format     Abstract available


  174. WANG H, Liu Y, Tian Q, Yang J, et al
    Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: a meta-analysis of randomised controlled trials.
    Diabetes Obes Metab. 2017 Nov 30. doi: 10.1111/dom.13177.
    PubMed     Text format     Abstract available


  175. LOUGHLIN AM, Qiao Q, Nunes AP, Ohman P, et al
    Effectiveness and tolerability of therapy with exenatide once-weekly versus basal insulin among injectable-naive elderly or renal impaired patients with type 2 diabetes in the United States.
    Diabetes Obes Metab. 2017 Nov 30. doi: 10.1111/dom.13175.
    PubMed     Text format     Abstract available


  176. HART HUBERTA E, Rutten Guy E, Bontje Kyra N, Vos Rimke C, et al
    Overtreatment of older patients with type 2 diabetes mellitus in primary care.
    Diabetes Obes Metab. 2017 Nov 30. doi: 10.1111/dom.13174.
    PubMed     Text format     Abstract available


  177. BOTHA S, Forde L, MacNaughton S, Shearer R, et al
    The effect of non-surgical weight management on weight and glycaemic control in people with type 2 diabetes: a comparison of interventional and non-interventional outcomes at three years.
    Diabetes Obes Metab. 2017 Nov 27. doi: 10.1111/dom.13171.
    PubMed     Text format     Abstract available


  178. TAY J, Thompson CH, Luscombe-Marsh ND, Wycherley TP, et al
    Effects of an energy-restricted low-carbohydrate, high unsaturated fat/low saturated fat diet versus a high carbohydrate, low fat diet in type 2 diabetes: a 2 year randomized clinical trial.
    Diabetes Obes Metab. 2017 Nov 27. doi: 10.1111/dom.13164.
    PubMed     Text format     Abstract available


  179. VILSBOLL T, Bain SC, Leiter LA, Lingvay I, et al
    Semaglutide, reduction in HbA1c and the risk of diabetic retinopathy.
    Diabetes Obes Metab. 2017 Nov 27. doi: 10.1111/dom.13172.
    PubMed     Text format     Abstract available


  180. YE M, Robson PJ, Eurich DT, Vena JE, et al
    Systemic Use of Antibiotics and Risk of Diabetes in Adults: A Nested Case-control Study of Alberta's Tomorrow Project.
    Diabetes Obes Metab. 2017 Nov 20. doi: 10.1111/dom.13163.
    PubMed     Text format     Abstract available


  181. CHEN Y, Liu X, Li Q, Ma J, et al
    Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: results from the SUPER study, a randomized, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2017 Nov 16. doi: 10.1111/dom.13161.
    PubMed     Text format     Abstract available


  182. MCGOVERN A, Tippu Z, Hinton W, Munro N, et al
    A comparison of adherence and persistence by medication class in type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2017 Nov 14. doi: 10.1111/dom.13160.
    PubMed     Text format     Abstract available


  183. TONG L, Pan C, Wang H, Bertolini M, et al
    Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: a longitudinal study of a US administrative claims database.
    Diabetes Obes Metab. 2017 Nov 8. doi: 10.1111/dom.13156.
    PubMed     Text format     Abstract available


  184. CHAN LKY, Wang Y, Ng EKW, Leung PS, et al
    NHE3 Blockade Ameliorates Type 2 Diabetes Mellitus via Inhibition of SGLT1-Mediated Glucose Absorption in the Small Intestine.
    Diabetes Obes Metab. 2017 Nov 7. doi: 10.1111/dom.13151.
    PubMed     Text format     Abstract available


  185. INAGAKI N, Harashima SI, Kaku K, Kondo K, et al
    Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2017 Nov 7. doi: 10.1111/dom.13152.
    PubMed     Text format     Abstract available


  186. JOURDAN T, Park JK, Varga ZV, Paloczi J, et al
    Cannabinoid-1 receptor deletion in podocytes mitigates both glomerular and tubular dysfunction in a mouse model of diabetic nephropathy.
    Diabetes Obes Metab. 2017 Nov 6. doi: 10.1111/dom.13150.
    PubMed     Text format     Abstract available


  187. SIEGMUND T, Tentolouris N, Knudsen ST, Lapolla A, et al
    A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes.
    Diabetes Obes Metab. 2017 Nov 6. doi: 10.1111/dom.13149.
    PubMed     Text format     Abstract available


  188. CHEN K, Kang D, Yu M, Zhang R, et al
    Direct head-to-head comparison of glycemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: a meta-analysis of long-term randomized controlled trials.
    Diabetes Obes Metab. 2017 Nov 2. doi: 10.1111/dom.13147.
    PubMed     Text format     Abstract available


  189. HERTROIJS DF, Elissen AM, Brouwers MC, Schaper NC, et al
    A risk score of BMI, HbA1c and triglycerides predicts future glycemic control in type 2 diabetes.
    Diabetes Obes Metab. 2017 Nov 2. doi: 10.1111/dom.13148.
    PubMed     Text format     Abstract available


    October 2017
  190. WITTBRODT E, Kong AM, Moore-Schiltz L, Juneau P, et al
    All-Cause and Diabetes-Related Healthcare Costs among U.S. Adults with Type 2 Diabetes Initiating Exenatide Once Weekly or Insulin Glargine.
    Diabetes Obes Metab. 2017 Oct 30. doi: 10.1111/dom.13145.
    PubMed     Text format     Abstract available


  191. SKOG O, Korsgren O
    On the etiology of type 1 diabetes: Physiological growth in children impacts disease progression.
    Diabetes Obes Metab. 2017 Oct 30. doi: 10.1111/dom.13144.
    PubMed     Text format     Abstract available


  192. KHUNTI K, Kosiborod M
    SGLT 2 inhibitors and cardiovascular outcome studies in Type 2 diabetes: From efficacy to effectiveness.
    Diabetes Obes Metab. 2017 Oct 27. doi: 10.1111/dom.13142.
    PubMed     Text format     Abstract available


  193. CASPARD H, Jabbour S, Hammar N, Fenici P, et al
    Recent Trends in the Prevalence of Type 2 Diabetes and the Association With Abdominal Obesity Lead to Growing Health Disparities in the United States.
    Diabetes Obes Metab. 2017 Oct 27. doi: 10.1111/dom.13143.
    PubMed     Text format     Abstract available


  194. GEYER MC, Rayner CK, Horowitz M, Couper JJ, et al
    Targeting Postprandial Glycaemia in Children with Diabetes: Opportunities and Challenges.
    Diabetes Obes Metab. 2017 Oct 26. doi: 10.1111/dom.13141.
    PubMed     Text format     Abstract available


  195. HUANG J, Yang Y, Hu R, Chen L, et al
    Anti-interleukin-1 therapy has mild hypoglycemic effect in type 2 diabetes.
    Diabetes Obes Metab. 2017 Oct 26. doi: 10.1111/dom.13140.
    PubMed     Text format     Abstract available


  196. SHAH A, Levesque K, Pierini E, Rojas B, et al
    Effect of Sitagliptin on Glucose Control in Type 2 Diabetes Mellitus after Roux-en-Y Gastric Bypass Surgery.
    Diabetes Obes Metab. 2017 Oct 26. doi: 10.1111/dom.13139.
    PubMed     Text format     Abstract available


  197. HWANG YC, Morrow DA, Cannon CP, Liu Y, et al
    High-sensitivity C-reactive Protein, Low-Density Lipoprotein Cholesterol, and Cardiovascular Outcomes in Patients with Type 2 Diabetes in the EXAMINE (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) Trial.
    Diabetes Obes Metab. 2017 Oct 24. doi: 10.1111/dom.13136.
    PubMed     Text format     Abstract available


  198. TANG T, Abbott S, le Roux CW, Wilson V, et al
    Preoperative Weight Loss With GLP-1 Receptor Agonist Treatment Predicts Greater Weight Loss Achieved by the Combination of Medical Weight Management And Bariatric Surgery In Patients With Type 2 Diabetes: A Longitudinal Analysis.
    Diabetes Obes Metab. 2017 Oct 20. doi: 10.1111/dom.13131.
    PubMed     Text format     Abstract available


  199. HENRY R, Rosenstock J, McCarthy JF, Carls G, et al
    Treatment Satisfaction with ITCA 650, a Novel Drug-device Delivering Continuous Exenatide versus Twice-Daily Injections of Exenatide in Type 2 Diabetics on Metformin.
    Diabetes Obes Metab. 2017 Oct 20. doi: 10.1111/dom.13133.
    PubMed     Text format     Abstract available


  200. TOP W, Stehouwer C, Lehert P, Kooy A, et al
    Metformin and beta cell function in insulin-treated patients with type 2 diabetes : a randomized placebo-controlled 4.3 year trial.
    Diabetes Obes Metab. 2017 Oct 2. doi: 10.1111/dom.13123.
    PubMed     Text format     Abstract available


    September 2017
  201. JABBOUR S, Seufert J, Scheen A, Bailey CJ, et al
    Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from Phase 2b/3 clinical trials.
    Diabetes Obes Metab. 2017 Sep 26. doi: 10.1111/dom.13124.
    PubMed     Text format     Abstract available


  202. MARFELLA R, Sardu C, Calabro P, Siniscalchi M, et al
    Non-ST-Elevation Myocardial Infarction (NSTEMI) outcome in type 2 diabetic patients with non-obstructive coronary artery stenosis: effects of incretin treatment.
    Diabetes Obes Metab. 2017 Sep 26. doi: 10.1111/dom.13122.
    PubMed     Text format     Abstract available


  203. PANG B, Zhao LH, Li XL, Song J, et al
    Different intervention strategies for preventing type 2 diabetes mellitus in China: A systematic review and network meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2017 Sep 23. doi: 10.1111/dom.13121.
    PubMed     Text format     Abstract available


  204. HULST AH, Polderman JAW, Ouweneel E, Pijl AJ, et al
    Perioperative continuation of metformin does not improve glycemic control in patients with type 2 diabetes; a randomized controlled trial.
    Diabetes Obes Metab. 2017 Sep 20. doi: 10.1111/dom.13118.
    PubMed     Text format     Abstract available


  205. DOU J, Ma J, Liu J, Wang C, et al
    Efficacy and Safety of Saxagliptin in Combination with Metformin as Initial Therapy in Chinese Patients with Type 2 diabetes: Results from the START Study, a Multicenter, Randomized, Double-blind, Active-controlled, Phase 3 Trial.
    Diabetes Obes Metab. 2017 Sep 19. doi: 10.1111/dom.13117.
    PubMed     Text format     Abstract available


  206. DAGOGO-JACK S, Liu J, Eldor R, Amorin G, et al
    Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study.
    Diabetes Obes Metab. 2017 Sep 17. doi: 10.1111/dom.13116.
    PubMed     Text format     Abstract available


  207. LEITER LA, Cariou B, Muller-Wieland D, Colhoun HM, et al
    Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.
    Diabetes Obes Metab. 2017 Sep 14. doi: 10.1111/dom.13114.
    PubMed     Text format     Abstract available


  208. YUAN Z, DeFalco FJ, Ryan PB, Schuemie MJ, et al
    Risk of Lower Extremity Amputations in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors in the United States: A Retrospective Cohort Study.
    Diabetes Obes Metab. 2017 Sep 12. doi: 10.1111/dom.13115.
    PubMed     Text format     Abstract available


  209. NYSTROM T, Holzmann MJ, Eliasson B, Svensson AM, et al
    Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes.
    Diabetes Obes Metab. 2017 Sep 8. doi: 10.1111/dom.13110.
    PubMed     Text format     Abstract available


  210. IDRIS I
    Highlights from the 77th Scientific Sessions of the American Diabetes Association Scientific Meeting, 9-13 June 2017, San Diego, USA.
    Diabetes Obes Metab. 2017;19:1329-1331.
    PubMed     Text format    


  211. UNNI S, Wittbrodt E, Ma J, Schauerhamer M, et al
    Comparative Effectiveness of Once-Weekly GLP-1 Receptor Agonists on 6-Month Glycemic Control and Weight Outcomes in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Sep 1. doi: 10.1111/dom.13107.
    PubMed     Text format     Abstract available


  212. RITZEL R, Roussel R, Giaccari A, Vora J, et al
    Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL: one-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes.
    Diabetes Obes Metab. 2017 Sep 1. doi: 10.1111/dom.13105.
    PubMed     Text format     Abstract available


  213. CERSOSIMO E, Johnson EL, Chovanes C, Skolnik N, et al
    Initiating therapy in patients newly diagnosed with type 2 diabetes: combination therapy versus a stepwise approach.
    Diabetes Obes Metab. 2017 Sep 1. doi: 10.1111/dom.13108.
    PubMed     Text format     Abstract available


  214. KOWLURU A
    Role of G-proteins in islet function in health and diabetes.
    Diabetes Obes Metab. 2017;19 Suppl 1:63-75.
    PubMed     Text format     Abstract available


  215. SEINO S, Sugawara K, Yokoi N, Takahashi H, et al
    beta-Cell signalling and insulin secretagogues: A path for improved diabetes therapy.
    Diabetes Obes Metab. 2017;19 Suppl 1:22-29.
    PubMed     Text format     Abstract available


  216. WELTERS A, Kluppel C, Mrugala J, Wormeyer L, et al
    NMDAR antagonists for the treatment of diabetes mellitus-Current status and future directions.
    Diabetes Obes Metab. 2017;19 Suppl 1:95-106.
    PubMed     Text format     Abstract available


    August 2017
  217. ROSENSTOCK J, Frias J, Pall D, Charbonnel B, et al
    Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
    Diabetes Obes Metab. 2017 Aug 31. doi: 10.1111/dom.13103.
    PubMed     Text format     Abstract available


  218. AGGARWAL N, Singla A, Mathieu C, Montanya E, et al
    Metformin extended-release versus immediate-release: an international, randomized, double-blind, head-to-head trial in pharmacotherapy-naive patients with type 2 diabetes.
    Diabetes Obes Metab. 2017 Aug 31. doi: 10.1111/dom.13104.
    PubMed     Text format     Abstract available


  219. KHUNTI K, Gomes MB, Pocock S, Shestakova MV, et al
    Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review.
    Diabetes Obes Metab. 2017 Aug 22. doi: 10.1111/dom.13088.
    PubMed     Text format     Abstract available


  220. NEUMANN U, Buhrer C, Blankenstein O, Kuhnen P, et al
    Primary sulfonylurea therapy in a newborn with transient neonatal diabetes due to a paternal uniparental disomy 6q24 (UPD6).
    Diabetes Obes Metab. 2017 Aug 17. doi: 10.1111/dom.13085.
    PubMed     Text format     Abstract available


  221. JOHANSEN RF, Sondergaard E, Linnebjerg H, Garhyan P, et al
    Attenuated Suppression of Lipolysis Explains Increases in Triglyceride Secretion and Concentration with Basal Insulin Peglispro (BIL) Relative to Insulin Glargine Treatment in Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2017 Aug 17. doi: 10.1111/dom.13087.
    PubMed     Text format     Abstract available


  222. GALLWITZ B, Dagogo-Jack S, Thieu V, Garcia-Perez LE, et al
    Effect of Once-weekly Dulaglutide on HbA1c and Fasting Blood Glucose in Patient Subpopulations by Gender, Duration of Diabetes, and Baseline HbA1c.
    Diabetes Obes Metab. 2017 Aug 17. doi: 10.1111/dom.13086.
    PubMed     Text format     Abstract available


  223. KHUNTI K, Godec TR, Medina J, Garcia-Alvarez L, et al
    Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany.
    Diabetes Obes Metab. 2017 Aug 17. doi: 10.1111/dom.13083.
    PubMed     Text format     Abstract available


  224. CRUTCHLOW M, Palcza JS, Mostoller KM, Mahon CD, et al
    Single Dose Euglycemic Clamp Studies Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between MK-1293 Insulin Glargine and Originator Insulin Glargine (Lantus) in Type 1 Diabetes and Healthy Subjects.
    Diabetes Obes Metab. 2017 Aug 17. doi: 10.1111/dom.13084.
    PubMed     Text format     Abstract available


  225. AHN CH, Oh TJ, Kwak SH, Cho YM, et al
    Sodium-Glucose Cotransporter-2 Inhibition Improves Incretin Sensitivity of Pancreatic beta-cells in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Aug 8. doi: 10.1111/dom.13081.
    PubMed     Text format     Abstract available


  226. SEINO Y, Terauchi Y, Osonoi T, Yabe D, et al
    Safety and efficacy of semaglutide once weekly versus sitagliptin once daily, both as monotherapy in Japanese subjects with type 2 diabetes.
    Diabetes Obes Metab. 2017 Aug 8. doi: 10.1111/dom.13082.
    PubMed     Text format     Abstract available


  227. KADOWAKI T, Inagaki N, Kondo K, Nishimura K, et al
    Efficacy and safety of teneligliptin added onto canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a multicentre, randomised, double-blind, placebo-controlled, parallel-group comparative study.
    Diabetes Obes Metab. 2017 Aug 8. doi: 10.1111/dom.13079.
    PubMed     Text format     Abstract available


  228. BRONDEN A, Alber A, Rohde U, Gasbjerg LS, et al
    The bile acid-sequestering resin sevelamer eliminates the acute GLP-1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes.
    Diabetes Obes Metab. 2017 Aug 8. doi: 10.1111/dom.13080.
    PubMed     Text format     Abstract available


  229. PERSSON F, Nystrom T, Jorgensen ME, Carstensen B, et al
    Dapagliflozin Compared to DPP-4 inhibitors is Associated with Lower Risk of Cardiovascular Events and All-cause Mortality in Type 2 Diabetes Patients (CVD-REAL Nordic): a multinational observational study.
    Diabetes Obes Metab. 2017 Aug 3. doi: 10.1111/dom.13077.
    PubMed     Text format     Abstract available


    July 2017
  230. YANG W, Min K, Zhou Z, Li L, et al
    The efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: the GetGoal-L-C randomized trial.
    Diabetes Obes Metab. 2017 Jul 25. doi: 10.1111/dom.13072.
    PubMed     Text format     Abstract available


  231. ROUSSEL R, d'Emden MC, Fisher M, Ampudia-Blasco FJ, et al
    Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
    Diabetes Obes Metab. 2017 Jul 24. doi: 10.1111/dom.13071.
    PubMed     Text format     Abstract available


  232. HEALD AH, Livingston M, Malipatil N, Becher M, et al
    Improving Type 2 Diabetes Mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes Audit.
    Diabetes Obes Metab. 2017 Jul 20. doi: 10.1111/dom.13067.
    PubMed     Text format     Abstract available


  233. PARTHSARATHY V, Hogg C, Flatt PR, O'Harte FPM, et al
    Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
    Diabetes Obes Metab. 2017 Jul 20. doi: 10.1111/dom.13068.
    PubMed     Text format     Abstract available


  234. SCHMITT C, Portron A, Jadidi S, Sarkar N, et al
    Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2017 Jul 20. doi: 10.1111/dom.13024.
    PubMed     Text format     Abstract available


  235. WAN EYF, Fong DYT, Fung CSC, Yu EYT, et al
    Development of a Cardiovascular Diseases Risk Prediction Model and Tools for Chinese Patients with Type 2 Diabetes Mellitus - A Population-based Retrospective Cohort Study.
    Diabetes Obes Metab. 2017 Jul 19. doi: 10.1111/dom.13066.
    PubMed     Text format     Abstract available


  236. DUBE MC, D'Amours M, Weisnagel SJ
    Beyond glycemic control: a cross-over, double-blind, 24 week intervention with liraglutide in type 1 diabetes.
    Diabetes Obes Metab. 2017 Jul 18. doi: 10.1111/dom.13063.
    PubMed     Text format     Abstract available


  237. SHIBUYA T, Fushimi N, Kawai M, Yoshida Y, et al
    Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study.
    Diabetes Obes Metab. 2017 Jul 18. doi: 10.1111/dom.13061.
    PubMed     Text format     Abstract available


  238. BERARD L, Bonnemaire M, Mical M, Edelman S, et al
    Insights into optimal basal insulin titration in type 2 diabetes: results of a quantitative survey.
    Diabetes Obes Metab. 2017 Jul 18. doi: 10.1111/dom.13064.
    PubMed     Text format     Abstract available


  239. HAN SY, Yoon SA, Han BG, Kim SG, et al
    Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Diabetes Obes Metab. 2017 Jul 18. doi: 10.1111/dom.13059.
    PubMed     Text format     Abstract available


  240. REDDY R, El Youssef J, Winters-Stone K, Branigan D, et al
    The impact of exercise on sleep in adults with type 1 diabetes.
    Diabetes Obes Metab. 2017 Jul 18. doi: 10.1111/dom.13065.
    PubMed     Text format     Abstract available


  241. WYSHAM CH, Rosenstock J, Vetter ML, Dong F, et al
    Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
    Diabetes Obes Metab. 2017 Jul 7. doi: 10.1111/dom.13056.
    PubMed     Text format     Abstract available


  242. OUT M, Miedema I, Jager-Wittenaar H, van der Schans C, et al
    Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A Post hoc Analysis of a Randomized Placebo-Controlled 4.3 year Trial.
    Diabetes Obes Metab. 2017 Jul 6. doi: 10.1111/dom.13054.
    PubMed     Text format     Abstract available


  243. GINGRAS V, Taleb N, Roy-Fleming A, Legault L, et al
    The challenges of Achieving Postprandial Glucose Control using Closed-Loop Systems in Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2017 Jul 4. doi: 10.1111/dom.13052.
    PubMed     Text format     Abstract available


  244. HELLER SR, Pratley RE, Sinclair A, Festa A, et al
    Glycaemic outcomes of an Individualised treatMent aPproach for oldER vulnerable patIents: A randomised, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM).
    Diabetes Obes Metab. 2017 Jul 3. doi: 10.1111/dom.13051.
    PubMed     Text format     Abstract available


    June 2017
  245. HOME PD, Bergenstal RM, Bolli GB, Ziemen M, et al
    Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).
    Diabetes Obes Metab. 2017 Jun 29. doi: 10.1111/dom.13048.
    PubMed     Text format     Abstract available


  246. GARRY EM, Buse JB, Lund JL, Pate V, et al
    Comparative Safety of Pioglitazone versus Clinically Meaningful Treatment Alternatives on the Risk of Bladder Cancer in Older US Adults with Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Jun 29. doi: 10.1111/dom.13049.
    PubMed     Text format     Abstract available


  247. WANG Z, Sun J, Han R, Fan D, et al
    Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2017 Jun 28. doi: 10.1111/dom.13047.
    PubMed     Text format     Abstract available


  248. BAJAJ HS, Ye C, Jain E, Venn K, et al
    Glycemic Improvement with a Fixed-dose combination of DPP-4 inhibitor + metformin in patients with Type 2 Diabetes (GIFT study).
    Diabetes Obes Metab. 2017 Jun 22. doi: 10.1111/dom.13040.
    PubMed     Text format     Abstract available


  249. TSUJIMOTO T, Kajio H, Sugiyama T
    Favourable Changes in Mortality in People with Diabetes - U.S. NHANES 1999-2010.
    Diabetes Obes Metab. 2017 Jun 22. doi: 10.1111/dom.13039.
    PubMed     Text format     Abstract available


  250. GROOP PH, Cooper ME, Perkovic V, Hocher B, et al
    Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.
    Diabetes Obes Metab. 2017 Jun 21. doi: 10.1111/dom.13041.
    PubMed     Text format     Abstract available


  251. KADOWAKI T, Inagaki N, Kondo K, Nishimura K, et al
    Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
    Diabetes Obes Metab. 2017 Jun 13. doi: 10.1111/dom.13038.
    PubMed     Text format     Abstract available


  252. CANOVATCHEL W, Davidson J, Rosenthal N
    Comment on Tang, et al. Sodium-glucose cotransporter 2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017; doi: 10.1111/dom.12
    Diabetes Obes Metab. 2017 Jun 9. doi: 10.1111/dom.13035.
    PubMed     Text format     Abstract available


  253. ROUSSEL R, Steg PG, Mohammedi K, Marre M, et al
    Prevention of Cardiovascular Disease by the Reduction of Glycemic Exposure in Type 2 Diabetes: A Perspective on Glucose-Lowering Interventions.
    Diabetes Obes Metab. 2017 Jun 9. doi: 10.1111/dom.13033.
    PubMed     Text format     Abstract available


  254. CONCEICAO J, Dores J, Araujo F, Laires P, et al
    Severe Hypoglycemia Among Patients With Type 2 Diabetes Requiring Emergency Hospital Admission: The HIPOS-ER Study.
    Diabetes Obes Metab. 2017 Jun 5. doi: 10.1111/dom.13030.
    PubMed     Text format     Abstract available


  255. GERSTEIN HC, Colhoun HM, Dagenais GR, Diaz R, et al
    Design and Baseline Characteristics of Participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) Trial of Dulaglutide's Cardiovascular Effects.
    Diabetes Obes Metab. 2017 Jun 1. doi: 10.1111/dom.13028.
    PubMed     Text format     Abstract available


  256. RUSSELL-JONES D, Heller S, Buchs S, Sandberg A, et al
    Projected Long-Term Outcomes in Patients With Type 1 Diabetes Treated With Fast-Acting Insulin Aspart Versus Conventional Insulin Aspart in the Uk Setting.
    Diabetes Obes Metab. 2017 Jun 1. doi: 10.1111/dom.13026.
    PubMed     Text format     Abstract available


    May 2017
  257. BONORA BM, Avogaro A, Fadini GP
    Sodium-Glucose Co-transporter-2 Inhibitors and Diabetic Ketoacidosis. An Updated Review of the Literature.
    Diabetes Obes Metab. 2017 May 18. doi: 10.1111/dom.13012.
    PubMed     Text format     Abstract available


  258. BROWN A, Guess N, Dornhorst A, Taheri S, et al
    Insulin-associated weight gain in obese type 2 diabetes mellitus patients - what can be done?
    Diabetes Obes Metab. 2017 May 16. doi: 10.1111/dom.13009.
    PubMed     Text format     Abstract available


  259. MARCINAK J, Cao C, Lee D, Ye Z, et al
    Fasiglifam for glycemic control in patients with type 2 diabetes: a phase 3, placebo-controlled study.
    Diabetes Obes Metab. 2017 May 11. doi: 10.1111/dom.13004.
    PubMed     Text format     Abstract available


  260. NORTON L, Shannon C, Fourcaudot M, Hu C, et al
    Sodium-glucose (SGLT) and Glucose (GLUT) Transporter Expression in the Kidney of Type 2 Diabetic Subjects.
    Diabetes Obes Metab. 2017 May 6. doi: 10.1111/dom.13003.
    PubMed     Text format     Abstract available


  261. REINSTADLER SJ, Stiermaier T, Eitel C, Metzler B, et al
    Relationship Between Diabetes and Ischemic Injury Among Patients with Revascularized ST-Elevation Myocardial Infarction: Diabetes and Myocardial Damage.
    Diabetes Obes Metab. 2017 May 5. doi: 10.1111/dom.13002.
    PubMed     Text format     Abstract available


  262. DASSAU E, Renard E, Place J, Farret A, et al
    Intraperitoneal Insulin Delivery Provides Superior Glycemic Regulation to Subcutaneous Insulin Delivery in Model Predictive Control-based Fully-automated Artificial Pancreas in Patients with Type 1 Diabetes: A Pilot Study.
    Diabetes Obes Metab. 2017 May 5. doi: 10.1111/dom.12999.
    PubMed     Text format     Abstract available


  263. OWENS DR, Monnier L, Hanefeld M
    A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.
    Diabetes Obes Metab. 2017 May 4. doi: 10.1111/dom.12998.
    PubMed     Text format     Abstract available


    April 2017
  264. GU S, Wang X, Qiao Q, Gao W, et al
    Cost-Effectiveness of Exenatide twice daily versus Insulin Glargine as add-on Therapy to Oral Anti-diabetic Agents in Type 2 Diabetes in China.
    Diabetes Obes Metab. 2017 Apr 28. doi: 10.1111/dom.12991.
    PubMed     Text format     Abstract available


  265. OWENS D, Bolli G, Charbonnel B, Haak T, et al
    Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/ml added to oral antidiabetes agents in type 2 diabetes.
    Diabetes Obes Metab. 2017 Apr 27. doi: 10.1111/dom.12966.
    PubMed     Text format     Abstract available


  266. TONNEIJCK L, Muskiet MHA, Smits MM, Hoekstra T, et al
    Postprandial renal haemodynamic effect of lixisenatide versus once-daily insulin glulisine in type 2 diabetes patients on insulin-glargine: an 8-week, randomised, open-label trial.
    Diabetes Obes Metab. 2017 Apr 27. doi: 10.1111/dom.12985.
    PubMed     Text format     Abstract available


  267. GANTZ I, Okamoto T, Ito Y, Okuyama K, et al
    A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly DPP-4 inhibitor, in Japanese patients with type 2 diabetes.
    Diabetes Obes Metab. 2017 Apr 27. doi: 10.1111/dom.12988.
    PubMed     Text format     Abstract available


  268. HANEFELD M, Arteaga JM, Leiter LA, Marchesini G, et al
    Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.
    Diabetes Obes Metab. 2017 Apr 27. doi: 10.1111/dom.12986.
    PubMed     Text format     Abstract available


  269. PARK J, Park SW, Yoon KH, Kim SR, et al
    Efficacy and Safety of Evogliptin Monotherapy in Patients with Type 2 Diabetes and Moderately Elevated HbA1c by Diet and Exercise.
    Diabetes Obes Metab. 2017 Apr 27. doi: 10.1111/dom.12987.
    PubMed     Text format     Abstract available


  270. DAVIES MJ, Leiter LA, Guerci B, Grunberger G, et al
    Impact of baseline HbA1c, diabetes duration and BMI on clinical outcomes in the LixiLan-O trial testing iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine and lixisenatide monocomponents.
    Diabetes Obes Metab. 2017 Apr 22. doi: 10.1111/dom.12980.
    PubMed     Text format     Abstract available


  271. ENGEL SS, Suryawanshi S, Stevens SR, Josse RG, et al
    Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Outcomes from TECOS.
    Diabetes Obes Metab. 2017 Apr 22. doi: 10.1111/dom.12983.
    PubMed     Text format     Abstract available


  272. FADINI GP, Saragoni S, Russo P, Degli Esposti L, et al
    Intraclass differences in the risk of hospitalisazion for heart failure among type 2 diabetic patients initiating a dipeptydil peptidase-4 inhibitor or a sulphonylurea. Results from the OsMed Health-DB registry.
    Diabetes Obes Metab. 2017 Apr 21. doi: 10.1111/dom.12979.
    PubMed     Text format     Abstract available


  273. OWENS DR, Monnier L, Barnett AH
    Future challenges and therapeutic opportunities in type 2 diabetes: changing the paradigm of current therapy.
    Diabetes Obes Metab. 2017 Apr 21. doi: 10.1111/dom.12977.
    PubMed     Text format     Abstract available


  274. CERIELLO A, De Cosmo S, Rossi MC, Lucisano G, et al
    Variability in HbA1c, blood pressure, lipid parameters and serum uric acid and risk of development of chronic kidney disease in type 2 diabetes.
    Diabetes Obes Metab. 2017 Apr 21. doi: 10.1111/dom.12976.
    PubMed     Text format     Abstract available


  275. GUMMESSON A, Nyman E, Knutsson M, Karpefors M, et al
    Effect of Weight Reduction on Hemoglobin A1c in weight loss trials of Type 2 Diabetes Patients.
    Diabetes Obes Metab. 2017 Apr 18. doi: 10.1111/dom.12971.
    PubMed     Text format     Abstract available


  276. SOLINI A, Rossi C, Mazzanti CM, Proietti A, et al
    SGLT2 and SGLT1 renal expression in patients with type 2 diabetes.
    Diabetes Obes Metab. 2017 Apr 17. doi: 10.1111/dom.12970.
    PubMed     Text format     Abstract available


  277. CUSI K, Sanyal AJ, Zhang S, Hartman ML, et al
    Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes.
    Diabetes Obes Metab. 2017 Apr 17. doi: 10.1111/dom.12973.
    PubMed     Text format     Abstract available


  278. BIESTER T, Aschemeier B, Fath M, Frey M, et al
    Effects of Dapagliflozin on Insulin-requirement, Glucose Excretion, and ss- Hydroxybutyrate levels are not related to Baseline HbA1c in Youth with Type 1 Diabetes.
    Diabetes Obes Metab. 2017 Apr 17. doi: 10.1111/dom.12975.
    PubMed     Text format     Abstract available


  279. MEIER JJ, Schenker N, Kahle M, Schliess F, et al
    Impact of insulin glargine and lixisenatide on beta cell function in patients with type 2 diabetes mellitus: a randomized open-label study.
    Diabetes Obes Metab. 2017 Apr 13. doi: 10.1111/dom.12968.
    PubMed     Text format     Abstract available


  280. ZIMMERMAN RS, Hobbs TM, Wells BJ, Kong SX, et al
    Association of Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Use and Rates of Acute Myocardial Infarction, Stroke, and Overall Mortality in Patients with Type 2 Diabetes Mellitus in a Large Integrated Health System.
    Diabetes Obes Metab. 2017 Apr 13. doi: 10.1111/dom.12969.
    PubMed     Text format     Abstract available


  281. ZGHEBI SS, Steinke DT, Carr MJ, Rutter MK, et al
    Examining Trends in Type 2 Diabetes Incidence, Prevalence and Mortality in the UK between 2004 and 2014.
    Diabetes Obes Metab. 2017 Apr 7. doi: 10.1111/dom.12964.
    PubMed     Text format     Abstract available


  282. CHILTON R, Tikkanen I, Hehnke U, Woerle HJ, et al
    Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension.
    Diabetes Obes Metab. 2017 Apr 6. doi: 10.1111/dom.12962.
    PubMed     Text format     Abstract available


  283. WYSHAM C, Bonadonna RC, Aroda VR, Puig-Domingo M, et al
    Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLa
    Diabetes Obes Metab. 2017 Apr 6. doi: 10.1111/dom.12961.
    PubMed     Text format     Abstract available


  284. METZGER M, Castaneda J, Reznik Y, Giorgino F, et al
    Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: an analysis from the OpT2mise randomized trial.
    Diabetes Obes Metab. 2017 Apr 4. doi: 10.1111/dom.12960.
    PubMed     Text format     Abstract available


    March 2017
  285. GUZMAN CB, Zhang XM, Liu R, Regev A, et al
    Treatment with LY2409021, a Glucagon Receptor Antagonist, Increases Liver Fat in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Mar 31. doi: 10.1111/dom.12958.
    PubMed     Text format     Abstract available


  286. RUAN Y, Thabit H, Leelarathna L, Hartnell S, et al
    Faster insulin action is associated with improved glycemic outcomes during closed-loop insulin delivery and sensor-augmented pump therapy in adults with type 1 diabetes.
    Diabetes Obes Metab. 2017 Mar 30. doi: 10.1111/dom.12956.
    PubMed     Text format     Abstract available


  287. TERAUCHI Y, Tamura M, Senda M, Gunji R, et al
    Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16 week randomized, double-blind, placebo-controlled multicentre trial.
    Diabetes Obes Metab. 2017 Mar 30. doi: 10.1111/dom.12957.
    PubMed     Text format     Abstract available


  288. LUNDKVIST P, Pereira MJ, Katsogiannos P, Sjostrom CD, et al
    Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: sustained reductions in bodyweight, glycaemia, and blood pressure over 1 year.
    Diabetes Obes Metab. 2017 Mar 27. doi: 10.1111/dom.12954.
    PubMed     Text format     Abstract available


  289. RODBARD HW, Tripathy D, Vidrio Velazquez M, Demissie M, et al
    Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: a randomised, 18-week, open-label, phase 3 trial (onset 3).
    Diabetes Obes Metab. 2017 Mar 27. doi: 10.1111/dom.12955.
    PubMed     Text format     Abstract available


  290. RANJAN A, Schmidt S, Damm-Frydenberg C, Holst J, et al
    Short-term Effects of Low Carbohydrate Diet on Glycaemic Parameters and Cardiovascular Risk Markers in Patients with Type 1 Diabetes - A Randomised Open-label Cross-over Trial.
    Diabetes Obes Metab. 2017 Mar 27. doi: 10.1111/dom.12953.
    PubMed     Text format     Abstract available


  291. YAMADA Y, Senda M, Naito Y, Tamura M, et al
    Reduction of postprandial glucose by lixisenatide versus sitagliptin in Japanese patients with type 2 diabetes on background insulin glargine: a randomised phase 4 study.
    Diabetes Obes Metab. 2017 Mar 26. doi: 10.1111/dom.12945.
    PubMed     Text format     Abstract available


  292. WILLIAMS R, de Vries F, Kothny W, Serban C, et al
    Cardiovascular safety of vildagliptin in patients with type 2 diabetes: a European multi-database, non-interventional post-authorization safety study.
    Diabetes Obes Metab. 2017 Mar 24. doi: 10.1111/dom.12951.
    PubMed     Text format     Abstract available


  293. KULKARNI M, Foraker RE, McNeill AM, Girman C, et al
    Evaluation of the Modified FINDRISC Diabetes Score to Identify Individuals at High Risk for Diabetes among Middle-aged White and Black ARIC Study Participants.
    Diabetes Obes Metab. 2017 Mar 21. doi: 10.1111/dom.12949.
    PubMed     Text format     Abstract available


  294. STAELS F, Moyson C, Mathieu C
    Metformin as add-on to intensive insulin therapy in type 1 diabetes mellitus.
    Diabetes Obes Metab. 2017 Mar 20. doi: 10.1111/dom.12948.
    PubMed     Text format     Abstract available


  295. GARG M, Ghanim H, Kuhadiya ND, Green K, et al
    Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes.
    Diabetes Obes Metab. 2017 Mar 17. doi: 10.1111/dom.12944.
    PubMed     Text format     Abstract available


  296. DU J, Liang L, Fang H, Xu F, et al
    Efficacy and Safety of Saxagliptin Compared with Acarbose in Chinese Patients with Type 2 Diabetes Mellitus Uncontrolled on Metformin Monotherapy: Results of a Phase IV Open-Label Randomized Controlled Study (The SMART Study).
    Diabetes Obes Metab. 2017 Mar 14. doi: 10.1111/dom.12942.
    PubMed     Text format     Abstract available


  297. VAN RAALTE DH, Verchere CB
    Improving glycemic control in type 2 diabetes: stimulate insulin secretion or provide beta-cell rest?
    Diabetes Obes Metab. 2017 Mar 14. doi: 10.1111/dom.12935.
    PubMed     Text format     Abstract available


  298. HEISE T, Norskov M, Nosek L, Kaplan K, et al
    Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes.
    Diabetes Obes Metab. 2017 Mar 14. doi: 10.1111/dom.12938.
    PubMed     Text format     Abstract available


  299. SALASTEKAR N, Desai T, Hauser T, Schaefer EJ, et al
    Salsalate Improves Glycemia in Overweight Persons With Diabetes Risk Factors of Stable Statin-Treated Cardiovascular Disease: a 30-month Randomized Placebo-Controlled Trial.
    Diabetes Obes Metab. 2017 Mar 14. doi: 10.1111/dom.12940.
    PubMed     Text format     Abstract available


  300. POZZILLI P, Norwood P, Jodar E, Davies MJ, et al
    A placebo-controlled, randomised trial of the addition of once weekly GLP-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
    Diabetes Obes Metab. 2017 Mar 14. doi: 10.1111/dom.12937.
    PubMed     Text format     Abstract available


  301. BOULANGER M, Al-Shahi Salman R, Kerssens J, Wild SH, et al
    Association between diabetes mellitus and incidence and case-fatality after stroke due to intracerebral haemorrhage: a retrospective population-based cohort study.
    Diabetes Obes Metab. 2017 Mar 9. doi: 10.1111/dom.12934.
    PubMed     Text format     Abstract available


  302. TERAUCHI Y, Yamada Y, Ishida H, Ohsugi M, et al
    The efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients aged 60 years or older with type 2 diabetes mellitus (START-J trial).
    Diabetes Obes Metab. 2017 Mar 9. doi: 10.1111/dom.12933.
    PubMed     Text format     Abstract available


  303. FLORY J, Stempniewicz N, Keating S, Gerhard T, et al
    Comparative Adherence to Diabetes Drugs: An Analysis of Electronic Health Records and Claims Data.
    Diabetes Obes Metab. 2017 Mar 7. doi: 10.1111/dom.12931.
    PubMed     Text format     Abstract available


  304. UMPIERREZ G, O'Neal D, DiGenio A, Goldenberg R, et al
    Lixisenatide reduces glycemic variability in insulin-treated patients with type 2 diabetes.
    Diabetes Obes Metab. 2017 Mar 3. doi: 10.1111/dom.12930.
    PubMed     Text format     Abstract available


  305. MAURICIO D, Meneghini L, Seufert J, Liao L, et al
    Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA.
    Diabetes Obes Metab. 2017 Mar 2. doi: 10.1111/dom.12927.
    PubMed     Text format     Abstract available


  306. STADLER M, Bollow E, Fritsch M, Kerner W, et al
    Prevalence of Elevated Liver Enzymes in Adults with Type 1 Diabetes: a Multicenter Analysis of the German/Austrian DPV Database.
    Diabetes Obes Metab. 2017 Mar 2. doi: 10.1111/dom.12929.
    PubMed     Text format     Abstract available


  307. NEAL B, Perkovic V, Matthews DR, Mahaffey KW, et al
    Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2017;19:387-393.
    PubMed     Text format     Abstract available


  308. DRIESSEN JH, van den Bergh JP, van Onzenoort HA, Henry RM, et al
    Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.
    Diabetes Obes Metab. 2017;19:421-428.
    PubMed     Text format     Abstract available


  309. KOZLOVSKI P, Fonseca M, Mohan V, Lukashevich V, et al
    Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies.
    Diabetes Obes Metab. 2017;19:429-435.
    PubMed     Text format     Abstract available


  310. CAMASTRA S, Astiarraga B, Tura A, Frascerra S, et al
    Effect of exenatide on postprandial glucose fluxes, lipolysis, and ss-cell function in non-diabetic, morbidly obese patients.
    Diabetes Obes Metab. 2017;19:412-420.
    PubMed     Text format     Abstract available


  311. KNAPEN LM, de Jong RG, Driessen JH, Keulemans YC, et al
    Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
    Diabetes Obes Metab. 2017;19:401-411.
    PubMed     Text format     Abstract available


  312. BAIN S, Druyts E, Balijepalli C, Baxter CA, et al
    Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.
    Diabetes Obes Metab. 2017;19:329-335.
    PubMed     Text format     Abstract available


  313. BETTGE K, Kahle M, Abd El Aziz MS, Meier JJ, et al
    Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
    Diabetes Obes Metab. 2017;19:336-347.
    PubMed     Text format     Abstract available


    February 2017
  314. DE BOER SA, Heerspink HJ, Juarez Orozco LE, van Roon AM, et al
    Effect of linagliptin on pulse wave velocity in early type 2 diabetes (RELEASE): a randomized, double-blind, controlled 26-week trial.
    Diabetes Obes Metab. 2017 Feb 28. doi: 10.1111/dom.12925.
    PubMed     Text format     Abstract available


  315. TANG H, Li D, Zhang J, Li Y, et al
    Sodium-glucose cotransporter 2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2017 Feb 27. doi: 10.1111/dom.12917.
    PubMed     Text format     Abstract available


  316. PENG XV, Marcinak JF, Raanan MG, Cao C, et al
    Combining the GPR40 agonist fasiglifam with sitagliptin improves glycemic control in patients with type 2 diabetes with or without metformin: a randomized, 12-week trial.
    Diabetes Obes Metab. 2017 Feb 27. doi: 10.1111/dom.12921.
    PubMed     Text format     Abstract available


  317. LIAN JX, McGhee SM, So C, Chau J, et al
    Five-year cost-effectiveness of Patient Empowerment Programme (PEP) for type 2 diabetes mellitus in primary care.
    Diabetes Obes Metab. 2017 Feb 23. doi: 10.1111/dom.12919.
    PubMed     Text format     Abstract available


  318. ALBER A, Bronden A, Knop FK
    Short-acting GLP-1 receptor agonists as add-on to insulin therapy in type 1 diabetes - a review.
    Diabetes Obes Metab. 2017 Feb 17. doi: 10.1111/dom.12911.
    PubMed     Text format     Abstract available


  319. PAUL SK, Owusu Adjah ES, Samanta M, Patel K, et al
    Comparison of body mass index at diagnosis of diabetes in a multiethnic population: a case-control study with matched non-diabetic controls.
    Diabetes Obes Metab. 2017 Feb 17. doi: 10.1111/dom.12915.
    PubMed     Text format     Abstract available


  320. LEITER LA, Zamorano JL, Bujas-Bobanovic M, Louie MJ, et al
    Lipid-Lowering Efficacy and Safety of Alirocumab in Patients with or without Diabetes: A Sub-Analysis of ODYSSEY COMBO II.
    Diabetes Obes Metab. 2017 Feb 16. doi: 10.1111/dom.12909.
    PubMed     Text format     Abstract available


  321. ABERER F, Hajnsek M, Rumpler M, Zenz S, et al
    Evaluation of Subcutaneous Glucose Monitoring Systems under Routine Environmental Conditions in Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2017 Feb 16. doi: 10.1111/dom.12907.
    PubMed     Text format     Abstract available


  322. GADDE KM, Vetter ML, Iqbal N, Hardy E, et al
    Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study.
    Diabetes Obes Metab. 2017 Feb 16. doi: 10.1111/dom.12908.
    PubMed     Text format     Abstract available


  323. BERGMARK BA, Cannon CP, White WB, Jarolim P, et al
    Baseline Adiponectin Concentration and Clinical Outcomes among Patients with Diabetes and Recent Acute Coronary Syndrome in the EXAMINE Trial.
    Diabetes Obes Metab. 2017 Feb 14. doi: 10.1111/dom.12905.
    PubMed     Text format     Abstract available


  324. KAZDA CM, Frias J, Foga I, Cui X, et al
    Treatment with the Glucagon Receptor Antagonist LY2409021 Increases Ambulatory Blood Pressure in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Feb 13. doi: 10.1111/dom.12904.
    PubMed     Text format     Abstract available


  325. SUCHER S, Markova M, Hornemann S, Pivovarova O, et al
    A comparison of the effects of diets high in animal or plant protein on metabolic and cardiovascular markers in type 2 diabetes - a randomized clinical trial.
    Diabetes Obes Metab. 2017 Feb 9. doi: 10.1111/dom.12901.
    PubMed     Text format     Abstract available


  326. ALATORRE C, Fernandez Lando L, Yu M, Brown K, et al
    Treatment Patterns in Patients with Type 2 Diabetes Mellitus Treated with GLP-1 Receptor Agonists: Higher Adherence and Persistence with Dulaglutide Compared to Exenatide QW and Liraglutide.
    Diabetes Obes Metab. 2017 Feb 9. doi: 10.1111/dom.12902.
    PubMed     Text format     Abstract available


  327. KRAMER CK, Zinman B, Choi H, Connelly PW, et al
    Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes.
    Diabetes Obes Metab. 2017 Feb 9. doi: 10.1111/dom.12858.
    PubMed     Text format     Abstract available


  328. KADOWAKI T, Inagaki N, Kondo K, Nishimura K, et al
    Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: results of a 24-week, randomised, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2017 Feb 8. doi: 10.1111/dom.12898.
    PubMed     Text format     Abstract available


    January 2017
  329. RATHMANN W, Strassburger K, Bongaerts B, Bobrov P, et al
    Impact of Insulin Sensitivity, Beta-cell Function and Glycemic Control on Initiation of Second-Line Glucose-Lowering Treatment in Newly Diagnosed Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Jan 27. doi: 10.1111/dom.12894.
    PubMed     Text format     Abstract available


  330. GRAY SG, McGuire T, Cohen N, Little PJ, et al
    The emerging role of Metformin in Gestational Diabetes Mellitus.
    Diabetes Obes Metab. 2017 Jan 27. doi: 10.1111/dom.12893.
    PubMed     Text format     Abstract available


  331. ANHOLM C, Kumarathurai P, Pedersen LR, Nielsen OW, et al
    Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
    Diabetes Obes Metab. 2017 Jan 26. doi: 10.1111/dom.12891.
    PubMed     Text format     Abstract available


  332. HUNT B, Vega-Hernandez G, Valentine WJ, Kragh N, et al
    Evaluation of the long-term cost-effectiveness of liraglutide versus lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.
    Diabetes Obes Metab. 2017 Jan 26. doi: 10.1111/dom.12890.
    PubMed     Text format     Abstract available


  333. HARRIS SB, Kocsis G, Prager R, Ridge T, et al
    Safety and Efficacy of IDegLira Titrated Once Weekly versus Twice Weekly in Patients with Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Randomized Clinical Trial.
    Diabetes Obes Metab. 2017 Jan 26. doi: 10.1111/dom.12892.
    PubMed     Text format     Abstract available


  334. NYSTROM T, Bodegard J, Nathanson D, Thuresson M, et al
    Novel oral glucose-lowering drugs compared to insulin are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycemia in type 2 diabetes patients.
    Diabetes Obes Metab. 2017 Jan 24. doi: 10.1111/dom.12889.
    PubMed     Text format     Abstract available


  335. TERRA SG, Focht K, Davies M, Frias J, et al
    A Phase 3, Efficacy and Safety Study of Ertugliflozin Monotherapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise Alone.
    Diabetes Obes Metab. 2017 Jan 24. doi: 10.1111/dom.12888.
    PubMed     Text format     Abstract available


  336. STORGAARD H, Cold F, Gluud LL, Vilsboll T, et al
    Glucagon-Like Peptide-1 Agonists and Risk of Acute Pancreatitis in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Jan 20. doi: 10.1111/dom.12885.
    PubMed     Text format     Abstract available


  337. JI L, Zhang P, Zhu D, Li X, et al
    Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China.
    Diabetes Obes Metab. 2017 Jan 20. doi: 10.1111/dom.12886.
    PubMed     Text format     Abstract available


  338. VON SCHOLTEN BJ, Persson F, Rosenlund S, Eugen-Olsen J, et al
    Liraglutide effects on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomised, placebo-controlled, double-blind, cross-over trial.
    Diabetes Obes Metab. 2017 Jan 20. doi: 10.1111/dom.12884.
    PubMed     Text format     Abstract available


  339. HENRY RR, Dandona P, Pettus J, Mudaliar S, et al
    Dapagliflozin in Patients with Type 1 Diabetes: A post-hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting beta-hydroxybutyrate levels from a Phase IIa pilot study.
    Diabetes Obes Metab. 2017 Jan 18. doi: 10.1111/dom.12882.
    PubMed     Text format     Abstract available


  340. RIZZO M, Rizvi AA, Sesti G
    Cardiovascular Effects of GLP-1 Receptor Agonist Therapies in Patients with Type-1 Diabetes.
    Diabetes Obes Metab. 2017 Jan 18. doi: 10.1111/dom.12883.
    PubMed     Text format    


  341. HAIDAR A, Messier V, Legault L, Ladouceur M, et al
    Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: an open-label, randomised, crossover, controlled trial.
    Diabetes Obes Metab. 2017 Jan 17. doi: 10.1111/dom.12880.
    PubMed     Text format     Abstract available


  342. KIRK RK, Pyke C, von Herrath MG, Hasselby JP, et al
    Immunohistochemical Assessment of Glucagon-like Peptide 1 Receptor (GLP-1R) Expression in the Pancreas of Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Jan 17. doi: 10.1111/dom.12879.
    PubMed     Text format     Abstract available


  343. TSUJIMOTO T, Sugiyama T, Kajio H
    Effects of beta-blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease.
    Diabetes Obes Metab. 2017 Jan 17. doi: 10.1111/dom.12878.
    PubMed     Text format     Abstract available


  344. GOLDENBERG R, Gantz I, Andryuk PJ, O'Neill EA, et al
    Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled
    Diabetes Obes Metab. 2017 Jan 17. doi: 10.1111/dom.12832.
    PubMed     Text format     Abstract available


  345. DESAI M, Yavin Y, Balis D, Sun D, et al
    Renal Safety of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Patients With Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2017 Jan 12. doi: 10.1111/dom.12876.
    PubMed     Text format     Abstract available


  346. JI L, Li L, Kuang J, Yang T, et al
    Efficacy and safety of fixed-dose combination therapy alogliptin plus metformin in Asian patients with type 2 diabetes: a phase 3 trial.
    Diabetes Obes Metab. 2017 Jan 11. doi: 10.1111/dom.12875.
    PubMed     Text format     Abstract available


  347. DASGUPTA K, Rosenberg E, Joseph L, Cooke AB, et al
    Physician Step prescription and Monitoring to improve ARTERial health (SMARTER): a randomized controlled trial in type 2 diabetes and hypertension.
    Diabetes Obes Metab. 2017 Jan 11. doi: 10.1111/dom.12874.
    PubMed     Text format     Abstract available


  348. HAASE M, Kahle M, Janert M, Meier JJ, et al
    Basal rate tests (24 h fasts) performed in type-1 diabetic subjects with either absolute fasting or snacks containing negligible carbohydrate amounts result in similar glucose profiles - a randomized controlled prospective trial.
    Diabetes Obes Metab. 2017 Jan 6. doi: 10.1111/dom.12868.
    PubMed     Text format     Abstract available


  349. PARK YJ, Warnock GL, Ao Z, Safikhan N, et al
    Dual Role of IL-1beta in Islet Amyloid Formation and its beta-Cell Toxicity: Implications in Type 2 Diabetes and Islet Transplantation.
    Diabetes Obes Metab. 2017 Jan 6. doi: 10.1111/dom.12873.
    PubMed     Text format     Abstract available


  350. HELLER SR, Bergenstal RM, White WB, Kupfer S, et al
    Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndromes: the EXAMINE trial.
    Diabetes Obes Metab. 2017 Jan 6. doi: 10.1111/dom.12871.
    PubMed     Text format     Abstract available


  351. PARK SE, Lee BW, Kim JH, Lee WJ, et al
    Effect of gemigliptin on glycemic variability in patients with type 2 diabetes.
    Diabetes Obes Metab. 2017 Jan 6. doi: 10.1111/dom.12869.
    PubMed     Text format     Abstract available


  352. HONG SM, Park CY, Hwang DM, Han KA, et al
    Efficacy and Safety of Adding Evogliptin versus Sitagliptin In Metformin-Treated Patients With Type 2 Diabetes: A 24-week Randomised, Controlled Trial With Open Label Extension.
    Diabetes Obes Metab. 2017 Jan 6. doi: 10.1111/dom.12870.
    PubMed     Text format     Abstract available


    December 2016
  353. AHN CH, Han KA, Yu JM, Nam JY, et al
    Efficacy and Safety of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Combination Treatment of Metformin and Sulfonylurea: a 24-week, multicenter, randomized, double-blind, place
    Diabetes Obes Metab. 2016 Dec 27. doi: 10.1111/dom.12866.
    PubMed     Text format     Abstract available


  354. GORDON J, McEwan P, Evans M, Puelles J, et al
    Managing glycaemia in older people with type 2 diabetes: a retrospective, primary care based cohort study, with economic assessment of patient outcomes.
    Diabetes Obes Metab. 2016 Dec 27. doi: 10.1111/dom.12867.
    PubMed     Text format     Abstract available


  355. MCEWAN P, Bennett H, Qin L, Bergenheim K, et al
    An alternative approach to modelling HbA1c trajectories in patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2016 Dec 27. doi: 10.1111/dom.12865.
    PubMed     Text format     Abstract available


  356. YOON SA, Han BG, Kim SG, Han SY, et al
    Efficacy, Safety, and Albuminuria-Reducing Effect of Gemigliptin in Korean Type 2 Diabetes Patients with Moderate to Severe Renal Impairment: A 12-Week, Double-blind Randomized Study (the GUARD Study).
    Diabetes Obes Metab. 2016 Dec 25. doi: 10.1111/dom.12863.
    PubMed     Text format     Abstract available


  357. PENA MJ, de Zeeuw D, Andress D, Brennan JJ, et al
    The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.
    Diabetes Obes Metab. 2016 Dec 25. doi: 10.1111/dom.12864.
    PubMed     Text format     Abstract available


  358. FORST T, Falk A, Andersen G, Fischer A, et al
    Effects of sequentially adding empagliflozin and linagliptin on alpha and beta cell function in type 2 diabetic patients on previous metformin treatment - An exploratory mechanistic study.
    Diabetes Obes Metab. 2016 Dec 23. doi: 10.1111/dom.12838.
    PubMed     Text format     Abstract available


  359. MOBINI R, Tremaroli V, Stahlman M, Karlsson F, et al
    Metabolic effects of Lactobacillus reuteri DSM 17938 in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
    Diabetes Obes Metab. 2016 Dec 23. doi: 10.1111/dom.12861.
    PubMed     Text format     Abstract available


  360. KHENSIER K, Kashyap S
    Canagliflozin versus placebo for post-bariatric patients with persistent type II diabetes; a randomized controlled trial (CARAT).
    Diabetes Obes Metab. 2016 Dec 20. doi: 10.1111/dom.12860.
    PubMed     Text format     Abstract available


  361. YABE D, Iwasaki M, Kuwata H, Haraguchi T, et al
    SGLT2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: a randomized, open-label, 3-arm parallel comparative exploratory study.
    Diabetes Obes Metab. 2016 Dec 19. doi: 10.1111/dom.12848.
    PubMed     Text format     Abstract available


  362. KAPITZA C, Nowotny I, Lehmann A, Bergmann K, et al
    Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog(R) in subjects with type 1 diabetes.
    Diabetes Obes Metab. 2016 Dec 17. doi: 10.1111/dom.12856.
    PubMed     Text format     Abstract available


  363. ARAKI E, Onishi Y, Asano M, Kim H, et al
    Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: DAISY trial.
    Diabetes Obes Metab. 2016 Dec 17. doi: 10.1111/dom.12853.
    PubMed     Text format     Abstract available


  364. NAIK S, Belfort-DeAguiar R, Sejling AS, Szepietowska B, et al
    Evaluation of the Counter-regulatory Responses to Hypoglycemia in Patients with Type 1 Diabetes during Opiate Receptor Blockade with Naltrexone.
    Diabetes Obes Metab. 2016 Dec 17. doi: 10.1111/dom.12855.
    PubMed     Text format     Abstract available


  365. NIMRI R, Bratina N, Kordonouri O, Avbelj Stefanija M, et al
    MD-Logic Overnight Type 1 Diabetes Control in Home Settings: Multicenter, Multinational, Single blind, Randomized Trial.
    Diabetes Obes Metab. 2016 Dec 16. doi: 10.1111/dom.12852.
    PubMed     Text format     Abstract available


  366. HTIKE ZZ, Zaccardi F, Papamargaritis D, Webb DR, et al
    Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes Systematic review and mixed-treatment comparison analysis.
    Diabetes Obes Metab. 2016 Dec 15. doi: 10.1111/dom.12849.
    PubMed     Text format     Abstract available


  367. DEJGAARD TF, Johansen NB, Frandsen CS, Asmar A, et al
    Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes.
    Diabetes Obes Metab. 2016 Dec 9. doi: 10.1111/dom.12841.
    PubMed     Text format     Abstract available


  368. HOME P
    Comment on Abd El Aziz et al, A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients, Diabetes Obesity Metab 2016; on line ahead of pub
    Diabetes Obes Metab. 2016 Dec 9. doi: 10.1111/dom.12842.
    PubMed     Text format    


  369. PETRIE JR, Chaturvedi N, Ford I, Hramiak I, et al
    Metformin in adults with type 1 diabetes: design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): an international multicentre trial.
    Diabetes Obes Metab. 2016 Dec 9. doi: 10.1111/dom.12840.
    PubMed     Text format     Abstract available


    November 2016
  370. KAKU K, Sumino S, Katou M, Nishiyama Y, et al
    A randomized, double-blind, phase III study to evaluate efficacy and safety of once-daily treatment of alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes.
    Diabetes Obes Metab. 2016 Nov 28. doi: 10.1111/dom.12837.
    PubMed     Text format     Abstract available


  371. PORKSEN N, Linnebjerg H, Garhyan P, Lam EC, et al
    Novel Hepato-Preferential Basal Insulin Peglispro (BIL) Does Not Differentially Affect Insulin Sensitivity Compared with Insulin Glargine in Patients with Type 1 and Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Nov 26. doi: 10.1111/dom.12834.
    PubMed     Text format     Abstract available


  372. FRANDSEN CS, Dejgaard TF, Andersen HU, Holst JJ, et al
    Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: a randomised, placebo-controlled, double-blind, parallel-group study.
    Diabetes Obes Metab. 2016 Nov 21. doi: 10.1111/dom.12830.
    PubMed     Text format     Abstract available


  373. AHN CH, Kim EK, Min SH, Oh TJ, et al
    Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Lipid Metabolism and Endotoxemia after a High-Fat Meal in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Nov 21. doi: 10.1111/dom.12831.
    PubMed     Text format     Abstract available


  374. MOKHLESI B, Grimaldi D, Beccuti G, Van Cauter E, et al
    Effect of One Week of CPAP Treatment of Obstructive Sleep Apnoea on 24-h Profiles of Glucose, Insulin and Counter-regulatory Hormones in Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Nov 17. doi: 10.1111/dom.12823.
    PubMed     Text format     Abstract available


  375. WEI W, Buysman E, Grabner M, Xie L, et al
    A Real-world Study of Treatment Patterns and Outcomes in US Managed-Care Patients With Type 2 Diabetes Initiating Injectable Therapies.
    Diabetes Obes Metab. 2016 Nov 17. doi: 10.1111/dom.12828.
    PubMed     Text format     Abstract available


  376. PREISS D, Dawed A, Welsh P, Heggie A, et al
    The sustained influence of metformin therapy on circulating GLP-1 levels in individuals with and without type 2 diabetes.
    Diabetes Obes Metab. 2016 Nov 13. doi: 10.1111/dom.12826.
    PubMed     Text format     Abstract available


  377. LI D, Wang T, Shen S, Fang Z, et al
    Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2016 Nov 12. doi: 10.1111/dom.12825.
    PubMed     Text format     Abstract available


  378. GHOLAP NN, Achana FA, Davies MJ, Ray KK, et al
    Long-term mortality following acute myocardial infarction among those with and without diabetes: A systematic review and meta-analysis of studies in the post reperfusion era.
    Diabetes Obes Metab. 2016 Nov 12. doi: 10.1111/dom.12827.
    PubMed     Text format     Abstract available


  379. RAYNER CK, Jones KL, Wu T, Horowitz M, et al
    Gut feelings about diabetes and GLP-1 receptor agonists - lessons to be learnt from studies in functional gastrointestinal disorders.
    Diabetes Obes Metab. 2016 Nov 9. doi: 10.1111/dom.12822.
    PubMed     Text format    


  380. VAN MUNSTER SN, van der Graaf Y, de Valk HW, Visseren FL, et al
    Effect modification in the relation between HbA1c and cardiovascular disease and mortality in patients with type 2 diabetes.
    Diabetes Obes Metab. 2016 Nov 2. doi: 10.1111/dom.12820.
    PubMed     Text format     Abstract available


  381. LAUGIER-ROBIOLLE S, Verges B, Le Bras M, Gand E, et al
    Glycemic control impacts the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes.
    Diabetes Obes Metab. 2016 Nov 2. doi: 10.1111/dom.12819.
    PubMed     Text format     Abstract available


  382. YABE D, Eto T, Shiramoto M, Irie S, et al
    Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycemia in Japanese subjects with type 2 diabetes: a randomized, open-label, 2 arm parallel comparative, exploratory trial.
    Diabetes Obes Metab. 2016 Nov 1. doi: 10.1111/dom.12817.
    PubMed     Text format     Abstract available


  383. MITCHELL PL, Nachbar R, Lachance D, St-Pierre P, et al
    Treatment with a novel agent combining docosahexaenoate and metformin increases protectin DX and IL-6 production in skeletal muscle and reduces insulin resistance in obese diabetic db/db mice.
    Diabetes Obes Metab. 2016 Nov 1. doi: 10.1111/dom.12818.
    PubMed     Text format     Abstract available


    October 2016
  384. BLONDE L, Chava P, Dex T, Lin J, et al
    Predictors of type 2 diabetes patients' outcomes in the lixisenatide GetGoal clinical trials.
    Diabetes Obes Metab. 2016 Oct 21. doi: 10.1111/dom.12815.
    PubMed     Text format     Abstract available


  385. TUTTLE KR, Dwight McKinney T, Davidson JA, Anglin G, et al
    The Effects of Once Weekly Dulaglutide on Kidney Function in Patients with Type 2 Diabetes in Phase 2 and 3 Clinical Trials.
    Diabetes Obes Metab. 2016 Oct 21. doi: 10.1111/dom.12816.
    PubMed     Text format     Abstract available


  386. BROGLIO F, Mannucci E, Napoli R, Nicolucci A, et al
    Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: a meta-analysis from the GetGoal program.
    Diabetes Obes Metab. 2016 Oct 20. doi: 10.1111/dom.12810.
    PubMed     Text format     Abstract available


  387. TINAHONES FJ, Gallwitz B, Nordaby M, Gotz S, et al
    Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: two 24-week randomized, double-blind, double-dummy, parallel-group trials.
    Diabetes Obes Metab. 2016 Oct 20. doi: 10.1111/dom.12814.
    PubMed     Text format     Abstract available


  388. WU T, Xie C, Wu H, Jones KL, et al
    Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes.
    Diabetes Obes Metab. 2016 Oct 20. doi: 10.1111/dom.12812.
    PubMed     Text format     Abstract available


  389. MADJD A, Taylor MA, Delavari A, Malekzadeh R, et al
    Beneficial effects of replacing diet beverages with water on type 2 diabetic obese women following a hypo-energetic diet: A randomized, 24-week clinical trial.
    Diabetes Obes Metab. 2016 Oct 16. doi: 10.1111/dom.12793.
    PubMed     Text format     Abstract available


  390. ABD EL AZIZ MS, Kahle M, Meier JJ, Nauck MA, et al
    A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.
    Diabetes Obes Metab. 2016 Oct 7. doi: 10.1111/dom.12804.
    PubMed     Text format     Abstract available


  391. SINGH S, Wright EE Jr, Kwan AY, Thompson JC, et al
    Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2016 Oct 7. doi: 10.1111/dom.12805.
    PubMed     Text format     Abstract available


  392. NAUCK MA, Kahle M, Baranov O, Deacon CF, et al
    A randomized controlled trial of adding the DPP-4 inhibitor sitagliptin to ongoing therapy with liraglutide (GLP-1 receptor agonist): Increases in intact GLP-1 and GIP, but no change in insulin, glucagon or plasma glucose following a mixed meal in pat
    Diabetes Obes Metab. 2016 Oct 6. doi: 10.1111/dom.12802.
    PubMed     Text format     Abstract available


  393. HEISE T, Zijlstra E, Nosek L, Rikte T, et al
    Pharmacological properties of faster-acting insulin aspart versus insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: a randomised, double-blind, crossover trial.
    Diabetes Obes Metab. 2016 Oct 6. doi: 10.1111/dom.12803.
    PubMed     Text format     Abstract available


  394. ROHDE U, Federspiel CA, Vilmann P, Langholz E, et al
    The Impact of EndoBarrier Gastrointestinal Liner in Obese Patients with Normal Glucose Tolerance and Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Oct 3. doi: 10.1111/dom.12800.
    PubMed     Text format     Abstract available


  395. CUSI K, Sanyal AJ, Zhang S, Hoogwerf BJ, et al
    Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.
    Diabetes Obes Metab. 2016;18 Suppl 2:50-58.
    PubMed     Text format     Abstract available


  396. MUDALIAR S, Henry RR, Ciaraldi TP, Armstrong DA, et al
    Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.
    Diabetes Obes Metab. 2016;18 Suppl 2:17-24.
    PubMed     Text format     Abstract available


  397. GRUNBERGER G, Chen L, Rodriguez A, Tinahones FJ, et al
    A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naive patients with type 2 diabetes: the IMAGINE 6 trial.
    Diabetes Obes Metab. 2016;18 Suppl 2:34-42.
    PubMed     Text format     Abstract available


    September 2016
  398. CHOWDHURY TA, Srirathan D, Abraham G, Oei EL, et al
    COULD METFORMIN BE USED IN PATIENTS WITH DIABETES AND ADVANCED CHRONIC KIDNEY DISEASE?
    Diabetes Obes Metab. 2016 Sep 30. doi: 10.1111/dom.12799.
    PubMed     Text format     Abstract available


  399. MOREIRA-LUCAS TS, Duncan AM, Rabasa-Lhoret R, Vieth R, et al
    Effect of vitamin D supplementation on oral glucose tolerance in individuals with low vitamin D status and increased risk for developing type 2 diabetes (EVIDENCE): a double-blind, randomized, placebo-controlled clinical trial.
    Diabetes Obes Metab. 2016 Sep 26. doi: 10.1111/dom.12794.
    PubMed     Text format     Abstract available


  400. MENSBERG P, Nyby S, Jorgensen PG, Storgaard H, et al
    Near-normalisation of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes.
    Diabetes Obes Metab. 2016 Sep 26. doi: 10.1111/dom.12797.
    PubMed     Text format     Abstract available


  401. LIM S, Han KA, Yu JM, Chamnan P, et al
    Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: a double-blind randomized controlled trial (INICOM study).
    Diabetes Obes Metab. 2016 Sep 13. doi: 10.1111/dom.12787.
    PubMed     Text format     Abstract available


  402. JOSSE RG, Majumdar SR, Zheng Y, Adler A, et al
    Sitagliptin and Risk of Fractures in Type 2 Diabetes: Results from the TECOS Trial.
    Diabetes Obes Metab. 2016 Sep 8. doi: 10.1111/dom.12786.
    PubMed     Text format     Abstract available


  403. TANG H, Cui W, Li D, Wang T, et al
    Sodium-glucose cotransporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2016 Sep 6. doi: 10.1111/dom.12785.
    PubMed     Text format     Abstract available


  404. BRAMLAGE P, Lanzinger S, Rathmann W, Gillessen A, et al
    Dyslipidaemia and its treatment in patients with type 2 diabetes - a joint analysis of the German DIVE and DPV registries.
    Diabetes Obes Metab. 2016 Sep 4. doi: 10.1111/dom.12783.
    PubMed     Text format     Abstract available


  405. VIEIRA A, Courtney M, Druelle N, Avolio F, et al
    beta-Cell replacement as a treatment for type 1 diabetes: an overview of possible cell sources and current axes of research.
    Diabetes Obes Metab. 2016;18 Suppl 1:137-43.
    PubMed     Text format     Abstract available


  406. REMEDI MS, Emfinger C
    Pancreatic beta-cell identity in diabetes.
    Diabetes Obes Metab. 2016;18 Suppl 1:110-6.
    PubMed     Text format     Abstract available


  407. BRERETON MF, Rohm M, Ashcroft FM
    beta-Cell dysfunction in diabetes: a crisis of identity?
    Diabetes Obes Metab. 2016;18 Suppl 1:102-9.
    PubMed     Text format     Abstract available


    August 2016
  408. JEFFERY N, Harries LW
    Beta cell differentiation status in type 2 diabetes.
    Diabetes Obes Metab. 2016 Aug 23. doi: 10.1111/dom.12778.
    PubMed     Text format     Abstract available


  409. CARLSON N, Hommel K, Olesen JB, Gerds TA, et al
    Metformin-associated risk of acute dialysis in patients with type 2 diabetes: A nationwide cohort study.
    Diabetes Obes Metab. 2016 Aug 18. doi: 10.1111/dom.12764.
    PubMed     Text format     Abstract available


  410. FRIAS JP, Nakhle S, Ruggles JA, Zhuplatov S, et al
    Exenatide once weekly improved 24-hour glucose control and reduced glycemic variability in metformin-treated patients with type 2 diabetes: a randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2016 Aug 16. doi: 10.1111/dom.12763.
    PubMed     Text format     Abstract available


  411. TAKAHARA M, Shiraiwa T, Katakami N, Matsuoka TA, et al
    Preference in time of insulin injection in type 2 diabetic patients treated with once-daily long-acting insulin analog.
    Diabetes Obes Metab. 2016 Aug 9. doi: 10.1111/dom.12762.
    PubMed     Text format    


  412. PAUL SK, Shaw J, Montvida O, Klein K, et al
    Weight gain in insulin treated patients by BMI categories at treatment initiation: New evidence from real-world data in patients with type 2 diabetes.
    Diabetes Obes Metab. 2016 Aug 9. doi: 10.1111/dom.12761.
    PubMed     Text format     Abstract available


  413. VAJDA EG, Logan D, Lasseter K, Armas D, et al
    Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2016 Aug 8. doi: 10.1111/dom.12752.
    PubMed     Text format     Abstract available


  414. BAIN SC, Feher M, Russell-Jones D, Khunti K, et al
    Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK.
    Diabetes Obes Metab. 2016 Aug 5. doi: 10.1111/dom.12760.
    PubMed     Text format     Abstract available


  415. INAGAKI N, Araki E, Oura T, Matsui A, et al
    The combination of dulaglutide and biguanide reduced body weight in Japanese patients with type 2 diabetes.
    Diabetes Obes Metab. 2016 Aug 3. doi: 10.1111/dom.12758.
    PubMed     Text format     Abstract available


  416. LINNEBJERG H, Lam EC, Zhang X, Seger ME, et al
    Duration of Action of Two Insulin Glargine Products, LY2963016 Insulin Glargine and Lantus(R) Insulin Glargine, in Subjects with Type 1 Diabetes Mellitus.
    Diabetes Obes Metab. 2016 Aug 3. doi: 10.1111/dom.12759.
    PubMed     Text format     Abstract available


  417. JI LN, Pan CY, Lu JM, Li H, et al
    Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
    Diabetes Obes Metab. 2016;18:775-82.
    PubMed     Text format     Abstract available


    July 2016
  418. VELLECCO V, Mitidieri E, Gargiulo A, Brancaleone V, et al
    Vascular effects of Linagliptin in Non Obese Diabetic (NOD) mice are glucose-independent and involve positive modulation of Endothelial Nitric Oxide Synthase (eNOS)/caveolin-1 (CAV-1) pathway.
    Diabetes Obes Metab. 2016 Jul 27. doi: 10.1111/dom.12750.
    PubMed     Text format     Abstract available


  419. SMITS MM, Tonneijck L, Muskiet MH, Hoekstra T, et al
    Biliary effects of liraglutide and sitagliptin, a 12-week randomised placebo-controlled trial in type 2 diabetes patients.
    Diabetes Obes Metab. 2016 Jul 23. doi: 10.1111/dom.12748.
    PubMed     Text format     Abstract available


  420. ISHIHARA H, Yamaguchi S, Nakao I, Okitsu A, et al
    Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): A multi-centre, randomized, placebo-controlled, double-blind study.
    Diabetes Obes Metab. 2016 Jul 20. doi: 10.1111/dom.12745.
    PubMed     Text format     Abstract available


  421. TANG HL, Li DD, Zhang JJ, Hsu YH, et al
    Lack of Evidence for a Harmful Effect of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Fracture Risk among Type 2 Diabetes Patients: A Network and Cumulative Meta-Analysis of Randomized Controlled Trials.
    Diabetes Obes Metab. 2016 Jul 13. doi: 10.1111/dom.12742.
    PubMed     Text format     Abstract available


  422. GARG S, Selam JL, Bhargava A, Schloot N, et al
    Similar HbA1c Reduction and Hypoglycaemia with Variable- Vs Fixed-Time Dosing of Basal Insulin Peglispro (BIL) in Type 1 Diabetes: IMAGINE 7 Study.
    Diabetes Obes Metab. 2016 Jul 9. doi: 10.1111/dom.12740.
    PubMed     Text format     Abstract available


  423. GARG S, Dreyer M, Jinnouchi H, Mou J, et al
    A Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination with Prandial insulin Lispro, in Patients with Type 1 Diabetes: IMAGINE 1.
    Diabetes Obes Metab. 2016 Jul 8. doi: 10.1111/dom.12738.
    PubMed     Text format     Abstract available


  424. MATHIEU C, Herrera Mamolejo M, Gonzalez Gonzalez JG, Hansen L, et al
    Efficacy and Safety of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin Over 52 Weeks in Patients With Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Jul 7. doi: 10.1111/dom.12737.
    PubMed     Text format     Abstract available


  425. BAILEY TS, Takacs R, Tinahones FJ, Rao PV, et al
    Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.
    Diabetes Obes Metab. 2016 Jul 6. doi: 10.1111/dom.12736.
    PubMed     Text format     Abstract available


  426. SALSALI A, Kim G, Woerle HJ, Broedl UC, et al
    Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials.
    Diabetes Obes Metab. 2016 Jul 4. doi: 10.1111/dom.12734.
    PubMed     Text format     Abstract available


  427. AZAR ST, Echtay A, Wan Bebakar WM, Al Araj S, et al
    Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomised trial.
    Diabetes Obes Metab. 2016 Jul 4. doi: 10.1111/dom.12733.
    PubMed     Text format     Abstract available


  428. PARKINSON J, Tang W, Johansson CC, Boulton DW, et al
    Comparison of the exposure-response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2016;18:685-92.
    PubMed     Text format     Abstract available


  429. TIRUCHERAI GS, LaCreta F, Ismat FA, Tang W, et al
    Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2016;18:678-84.
    PubMed     Text format     Abstract available


    June 2016
  430. O'HARTE FP, Ng MT, Lynch AM, Conlon JM, et al
    Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.
    Diabetes Obes Metab. 2016 Jun 30. doi: 10.1111/dom.12713.
    PubMed     Text format     Abstract available


  431. DAVIES MJ, Russell-Jones D, Selam JL, Bailey TS, et al
    Basal insulin peglispro vs insulin glargine in insulin-naive type 2 diabetes: IMAGINE 2 randomized trial.
    Diabetes Obes Metab. 2016 Jun 28. doi: 10.1111/dom.12712.
    PubMed     Text format     Abstract available


  432. VAN DER SANDE NG, Dorresteijn JA, Visseren FL, Dwyer JP, et al
    Individualized prediction of the effect of angiotensin receptor inhibition on renal and cardiovascular outcomes in patients with diabetic nephropathy.
    Diabetes Obes Metab. 2016 Jun 23. doi: 10.1111/dom.12708.
    PubMed     Text format     Abstract available


  433. DAVIS TM, Badshah I, Chubb SA, Davis WA, et al
    Dose-response relationship between statin therapy and glycaemia in community-based patients with type 2 diabetes: The Fremantle Diabetes Study.
    Diabetes Obes Metab. 2016 Jun 23. doi: 10.1111/dom.12710.
    PubMed     Text format     Abstract available


  434. EKSTROM N, Svensson AM, Miftaraj M, Franzen S, et al
    Cardiovascular Safety of Glucose-Lowering Agents as Add-on Medication to Metformin Treatment in Type 2 Diabetes:Report from the Swedish National Diabetes Register (NDR).
    Diabetes Obes Metab. 2016 Jun 10. doi: 10.1111/dom.12704.
    PubMed     Text format     Abstract available


  435. JENDLE J, Testa MA, Martin S, Jiang H, et al
    Continuous Glucose Monitoring in Type 2 Diabetes Patients Treated with GLP-1 Receptor Agonist Dulaglutide in Combination with Prandial Insulin Lispro - An AWARD-4 Substudy.
    Diabetes Obes Metab. 2016 Jun 9. doi: 10.1111/dom.12705.
    PubMed     Text format     Abstract available


  436. WYSHAM C, Guerci B, D'Alessio D, Jia N, et al
    Baseline Factors Associated with Glycaemic Response to Treatment with Once Weekly Dulaglutide in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Jun 6. doi: 10.1111/dom.12702.
    PubMed     Text format     Abstract available


  437. MAGNUSSEN LV, Glintborg D, Hermann P, Hougaard DM, et al
    Effect of testosterone on insulin sensitivity, oxidative metabolism, and body-composition in aging men with type 2 diabetes on metformin monotherapy.
    Diabetes Obes Metab. 2016 Jun 6. doi: 10.1111/dom.12701.
    PubMed     Text format     Abstract available


  438. YOON KH, Nishimura R, Lee J, Crowe S, et al
    Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four Phase III trials.
    Diabetes Obes Metab. 2016 Jun 6. doi: 10.1111/dom.12699.
    PubMed     Text format     Abstract available


  439. BERGENSTAL RM, Lunt H, Franek E, Travert F, et al
    A Randomized, Double-Blind Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination with Prandial Insulin Lispro, in Patients with Type 1 Diabetes: IMAGINE 3.
    Diabetes Obes Metab. 2016 Jun 6. doi: 10.1111/dom.12698.
    PubMed     Text format     Abstract available


    May 2016
  440. BLEVINS T, Pieber TR, Vega GC, Zhang S, et al
    Randomized, Double-Blind Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination With Prandial Insulin Lispro, in Patients with Type 2 Diabetes: IMAGINE 4.
    Diabetes Obes Metab. 2016 May 28. doi: 10.1111/dom.12696.
    PubMed     Text format     Abstract available


  441. GERARDS MC, de Maar J, Steenbruggen TG, Hoekstra JB, et al
    Add-on treatment with intermediate-acting insulin versus sliding scale insulin for patients with type 2 diabetes or insulin resistance during cyclic glucocorticoid-containing antineoplastic chemotherapy - a randomized cross-over study.
    Diabetes Obes Metab. 2016 May 18. doi: 10.1111/dom.12694.
    PubMed     Text format     Abstract available


  442. APOVIAN C, Palmer K, Fain R, Perdomo C, et al
    Effects of Lorcaserin on Fat and Lean Mass Loss in Obese and Overweight Patients Without and With Type 2 Diabetes Mellitus: the BLOSSOM and BLOOM-DM Studies.
    Diabetes Obes Metab. 2016 May 13. doi: 10.1111/dom.12690.
    PubMed     Text format     Abstract available


  443. KAKU K, Enya K, Nakaya R, Ohira T, et al
    Long-term safety and efficacy of fasiglifam (TAK-875), a GPR40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study.
    Diabetes Obes Metab. 2016 May 13. doi: 10.1111/dom.12693.
    PubMed     Text format     Abstract available


  444. MORROW LA, Hompesch M, Jacober SJ, Choi SL, et al
    Glucodynamics of Long-Acting Basal Insulin Peglispro (BIL) Compared With Insulin Glargine at Steady State in Subjects with Type 1 Diabetes: substudy of a randomized crossover trial.
    Diabetes Obes Metab. 2016 May 12. doi: 10.1111/dom.12691.
    PubMed     Text format     Abstract available


  445. KHUNTI K, Alsifri S, Aronson R, Berkovic MC, et al
    Rates and predictors of hypoglycaemia in 27,585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study.
    Diabetes Obes Metab. 2016 May 10. doi: 10.1111/dom.12689.
    PubMed     Text format     Abstract available


  446. BOUSTANI MA, Pittman Iv I, Yu M, Thieu VT, et al
    Comparable efficacy and safety of once weekly dulaglutide in patients with type 2 diabetes >/=65 and <65 years of age.
    Diabetes Obes Metab. 2016 May 10. doi: 10.1111/dom.12687.
    PubMed     Text format     Abstract available


  447. PARRINELLO CM, Matsushita K, Woodward M, Wagenknecht LE, et al
    Risk prediction of major complications in persons with diabetes: The Atherosclerosis Risk in Communities Study.
    Diabetes Obes Metab. 2016 May 10. doi: 10.1111/dom.12686.
    PubMed     Text format     Abstract available


  448. SKOW MA, Bergmann NC, Knop FK
    Diabetes and obesity treatment based on dual incretin receptor activation - "twincretins".
    Diabetes Obes Metab. 2016 May 10. doi: 10.1111/dom.12685.
    PubMed     Text format     Abstract available


  449. RODBARD HW, Seufert J, Aggarwal N, Cao A, et al
    Efficacy and Safety of Titrated Canagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sitagliptin.
    Diabetes Obes Metab. 2016 May 10. doi: 10.1111/dom.12684.
    PubMed     Text format     Abstract available


  450. FU AZ, Sheehan J
    Treatment Intensification for Patients with Type 2 Diabetes and Poor Glycemic Control.
    Diabetes Obes Metab. 2016 May 10. doi: 10.1111/dom.12683.
    PubMed     Text format     Abstract available


  451. DEFRONZO RA, Chilton R, Norton L, Clarke G, et al
    Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
    Diabetes Obes Metab. 2016;18:454-62.
    PubMed     Text format     Abstract available


  452. WILDING JP, Overgaard RV, Jacobsen LV, Jensen CB, et al
    Exposure-response analyses of liraglutide 3.0 mg for weight management.
    Diabetes Obes Metab. 2016;18:491-9.
    PubMed     Text format     Abstract available


  453. MIKKELSEN KH, Allin KH, Knop FK
    Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literature.
    Diabetes Obes Metab. 2016;18:444-53.
    PubMed     Text format     Abstract available


  454. HODGE RJ, Nunez DJ
    Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?
    Diabetes Obes Metab. 2016;18:439-43.
    PubMed     Text format     Abstract available


  455. FREUDE S, Heise T, Woerle HJ, Jungnik A, et al
    Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11beta-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11beta-HSD1 inhibition after acute and multiple administrations over 2 weeks.
    Diabetes Obes Metab. 2016;18:483-90.
    PubMed     Text format     Abstract available


    January 2016
  456. WILKIN T, Greene S, McCrimmon R
    Testing the accelerator hypothesis: a new approach to type 1 diabetes prevention (adAPT 1).
    Diabetes Obes Metab. 2016;18:3-5.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: